




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68, C12P 19/34, C12N 15/10		A1	(11) International Publication Number: WO 96/38591 (43) International Publication Date: 5 December 1996 (05.12.96)
(21) International Application Number: PCT/US96/08501		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 June 1996 (03.06.96)			
(30) Priority Data:			
08/459,046	2 June 1995 (02.06.95)	US	
08/462,355	5 June 1995 (05.06.95)	US	
08/487,112	7 June 1995 (07.06.95)	US	
60/006,809	15 November 1995 (15.11.95)	US	
08/566,334	1 December 1995 (01.12.95)	US	
(71) Applicant: INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventor: GUEGLER, Karl, J.; 1048 Oakland Avenue, Menlo Park, CA 94025 (US).			
(74) Agent: GLAISTER, Debra, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).			

(54) Title: IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES



(57) Abstract

A method for obtaining longer cDNA sequences is provided. The method utilizes a known genomic DNA sequence or a partial cDNA sequence, such as can be obtained from GenBank partial cDNAs. Two PCR primers are designed to correspond to the ends of the known partial sequence and to anneal to DNA in a cDNA library so as to initiate extension away from the known cDNA and the other primer. The primers are added to a cDNA library with appropriate enzymes and extend through additional DNA sequence to produce PCR products, which are subsequently purified and sequenced to provide new sequences. The new sequences are then compared with the known partial cDNA sequence for areas of overlap, and the sequence is extended beyond the overlapping areas to provide longer DNA sequence.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES

TECHNICAL FIELD

The present invention is in the field of molecular biology
5 and more particularly, in the field of recombinant DNA technology.

BACKGROUND ART

PCR has become a widely used nucleic acid amplification technique since it was first presented by Kary Mullis at the Cold 10 Spring Harbor Symposium (Mullis K et al (1986) Cold Spring Harbor Symp Quant Biol 51: 263-273). PCR requires that a pair of primers be generated from known sequences. However, in many cases, sequence is available only from one end of a DNA segment. Several 15 methods have been developed to sequence an entire gene once a partial nucleotide sequence is available. As more partial cDNA sequences become available in the world's genetic databanks, more efficient and economical methods will be sought for then obtaining the complete gene.

PCR has become a widely used technique to complete genes for 20 which a partial sequence is already known. Gene-specific primers and primers located in the vector into which the cDNAs have been cloned are used for this purpose. However, this method is limited by the use of primers complementary to vector sequence which is common to all clones in the library. This results in an abundance 25 of non-specific PCR-products which have to be cloned and sequenced. Multiple rounds of amplifications with nested primers might be required. These additional operations increase the incorporation of errors.

Gobinda, Turner and Bolander (1993) in PCR Methods and Applications 2:318-22 disclose "restriction-site PCR" as a direct 30 method of retrieving unknown sequence which is adjacent to a known locus by using universal primers. First, genomic DNA is amplified in the presence of restriction site oligonucleotides and a primer

specific to the known region. Next, those products are subjected to a second round of PCR with the same restriction site oligonucleotides and another specific primer internal to the first one. Subsequently, the products of the last round of PCR are 5 transcribed with an appropriate RNA polymerase and sequenced with a reverse transcriptase and an end-labeled specific primer internal to the second specific PCR primer. Gobinda et al. present data concerning Factor IX for which they identified a 10 conserved stretch of 20 nucleotides in the 3' noncoding region of the gene.

Inverse PCR is the first method that reported successful acquisition of unknown sequences starting with primers based on a known region (Triglia T, Peterson MG, and Kemp DJ (1988) Nucleic Acids Res. 16:8186). Inverse PCR employs a strategy in which 15 several restriction enzymes are used to generate a suitable fragment in the known region. The segment is then circularized by intramolecular ligation and used as a PCR template with divergent primers created from the known region. However, the requirement of multiple restriction enzyme digestions followed by multiple 20 ligations (even before PCR is started) make the procedure slow and expensive (Gobinda et al. *Supra*).

Capture PCR, first disclosed by Lagerstrom M, Parik J, Malmgren H, Stewart J, Patterson U and Landegren U (1991) PCR Methods Applic. 1:111-19, is a method for PCR amplification of DNA 25 fragments adjacent to a known sequence in human and YAC DNA. As noted by Gobinda et al. *supra*, that method also requires multiple restriction enzyme digestions and ligation of an engineered double-stranded primer before PCR. Although the restriction and ligation reactions are carried out simultaneously in this method, 30 the requirement of extension reaction, immobilization of the extended product, two rounds of PCR and purification of template prior to sequencing render it cumbersome and time consuming as well.

Walking PCR, disclosed by Parker JD, Rabinovitch PS, and Burmer GC (1991) Nucleic Acids Res 19:3055-60, teaches a method for targeted gene walking via PCR. Although this method also permits retrieval of unknown sequence, Gobinda et al, *supra*, note that it requires oligomer-extension assay followed by identification and gel purification of the desired band prior to sequencing. Such extra steps again limit the applicability of the method.

The enzymes originally used in PCR were limited in their ability to reliably amplify long pieces of nucleic acids over 3kb. One of the explanations for this limitation seems to be the misincorporation of nucleotides resulting in non-basepairing mismatches which these enzymes often fail to extend.

Only the mixture of two enzymes, rTth DNA-Polymerase and Vent, the latter of which has so-called "proofreading" activity, and the optimization of amplification conditions finally overcame this limitation and made amplification of pieces of DNA of up to 40kb possible.

The most common way to identify genes expressed in a certain tissue at a certain time is the isolation of the mRNA of that particular tissue and the conversion of this mRNA into so-called cDNA (complementary DNA). This cDNAs are subsequently cloned into a vector (plasmid or Lambda) and amplified by transfection into E.coli cells resulting in a so-called cDNA library.

First and most important to researchers attempting to obtain a complete gene is that the enzymes used in converting mRNA into cDNA are limited in their ability to produce complete copies of the existing mRNAs. This requires the researcher to isolate multiple cDNA clones of the gene of interest using specific probes and analyze each of these isolates for a complete cDNA of the gene of interest. This process is called screening of cDNA libraries.

A major problem facing molecular biologists is finding the most efficient method to use to obtain a full-length cDNA from a

partial sequence. Such sequences are appearing with increasing frequency in GenBank, from commercial cDNA libraries and privately prepared libraries. The inventive method disclosed herein is a contribution to that art.

5

DISCLOSURE OF THE INVENTION

An improved method for extending the DNA sequence of a known fragment of DNA sequence is provided. The method may be used for extending known DNA sequences of genomic or cDNA origin. The method utilizes the polymerase chain reaction (PCR) and includes the steps of:

10 a) combining a first and second PCR primer with nucleic acid from a cDNA library, or pools of cDNA libraries, expected to contain said partial cDNA, or said partial cDNA that has been extended, or a genomic library, under conditions suitable for

15 synthesis of nucleic acid PCR products from the first and second primers, wherein said first and second primers are capable of annealing to opposite strands of the partial cDNA or genomic DNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA

20 polymerase in an antisense direction and the second primer is capable of being extended in a sense direction,

25 b) purifying the PCR products, and

c) identifying extended nucleotide sequences derived from said partial cDNA or said genomic DNA. In one embodiment of the present invention, the method of identifying the extended nucleotide sequences comprises nucleic acid sequencing. In another embodiment of the present invention, the method proceeds with repeating steps 6a through 6c on the nucleotide sequences identified in step 6c.

30

In another embodiment of the present invention, there is a method for extending the nucleotide sequence of a partial complementary DNA (cDNA) using polymerase chain reaction (PCR), comprising the steps of a) combining a first and second PCR primer

with nucleic acid from a cDNA library, or pools of cDNA libraries, expected to contain said partial cDNA, or said partial cDNA that has been extended, or a genomic DNA library, under conditions suitable for synthesis of nucleic acid PCR products from the first and second primers, wherein said first and second primers are capable of annealing to opposite strands of the partial cDNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA polymerase in an antisense direction and the second primer is capable of being extended in a sense direction,

- 10 b) purifying the PCR products,
- c) ligating the purified PCR products under conditions suitable for the formation of circular, closed nucleic acid,
- 15 d) transforming a host cell with the circular, closed nucleic acid and culturing the transformed host cell under conditions suitable for growth,
- e) recovering said circular closed nucleic acid from the cultured, transformed host cell, and
- 20 f) identifying extended nucleotide sequences derived from said partial cDNA or said genomic DNA.

The present invention also provides a method for extending known genomic DNA sequences which may be used for the detection and amplification of 5' untranslated nucleotide sequences and/or promoter sequences.

25 Also provided is an isolated DNA molecule comprising SEQ ID NO:11, the DNA for a novel human purinergic P2U receptor.

Also provided is an isolated DNA molecule comprising SEQ ID NO:12, the DNA for a novel human C5a-like seven transmembrane receptor.

30 These and other objects, advantages and features of the present invention will become apparent to those persons skilled in the art upon reading the details of the structure, synthesis, formulation and usage as more fully set forth below, reference

being made to the accompanying figures forming a part hereof.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 is a flow chart of the steps in the inventive method.

5 Figure 2 shows a typical plasmid obtained from the excision process of a lambdaZAP cDNA library. Typically 250-300 base pairs of the sequence are obtained in the high-throughput sequence operation. The clone is partially sequenced from the 5' end with T3 as a sequencing primer.

10 Figure 3 is a representation of the next step, in which pBLUESCRIPT SK plasmids in a cDNA library are used as a template and the two specially designed primers (XLR and XLS) amplify plasmids containing the gene of interest. Only plasmids containing priming sites for both XL-PCR primers and the gene of 15 interest will be amplified during the XL-PCR reaction.

20 Figure 4 is a representation of the amplified DNA segments which have been obtained through the XL-PCR reaction and consequently purified after separating the products on an agarose gel. For best results, the cDNA library used as a template should 25 be synthesized by random priming to assure the availability in this step of different amplified length of DNA (3' end) between the XLS priming site and the T7 priming site in the vector. The length of the 5' end (between the XLR priming site and the T3 priming site) in the vector will vary in size depending on how much of the mRNA of the gene of interest had been converted into cDNA during the cDNA library synthesis.

25 Figure 5 shows how the purified DNA segments containing the plasmid and the gene of interest are religated to form a circular plasmid and transformed into bacteria for amplification. Here 30 chemically competent E. coli cells were transformed and grown on petri dishes containing LB agar and 25 mg/L carbenicillin (2XCarb) for antibiotic selection.

Figure 6 shows schematically how pure samples of clones were

obtained from the different E. coli colonies grown in the procedure shown in Figure 5 (also Step 1 purification, Step 2 religation and Step 3 transformation in Figure 6). These clones are screened in Step 4 for additional sequence of the gene of interest at the 5' end. For this purpose the clones were analyzed by a PCR reaction employing the XLR primer and the T3 vector primer. The size of the resulting product will indicate how much additional sequence upstream of the XLR priming site each clone contains.

Figures 7A through 7H show the results of the inventive method, in which a partial sequence from Incyte clone 14770, which was similar to heat shock protein 90, was successively sequenced to obtain a full-length cDNA.

Figures 8A through 8F show the results of the inventive method, in which a partial sequence from Incyte clone 87058 which was similar to cathepsin was successively sequenced to obtain extensions of the cDNA.

MODES FOR CARRYING OUT THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference herein.

Before the present compounds, variants, formulations and methods for making and using such are described, it is to be understood that this invention is not limited to the particular compounds, variants, formulations or methods described, as such enzymes, formulations and methodologies may, of course, vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of protection will be limited only by the appended claims.

In the specification and appended claims, the singular forms

"a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a high-fidelity PCR enzyme" includes mixtures of such enzymes and any other enzymes fitting the stated criteria, reference to the 5 method includes reference to one or more methods for obtaining full-length cDNA sequences which will be known to those skilled in the art or will become known to them upon reading this specification.

The present method provides a way to utilize a genomic 10 DNA library or a plasmid cDNA library (either obtained by cloning cDNAs directly into a plasmid vector or by converting a Lambda library into a plasmid library by known methods e.g. Lambda ZAP excision or Lambda ZIPLOCK conversion) which has been used for sequencing cDNAs, as a source to obtain much longer DNAs and in 15 certain cases complete genes of partially known DNA sequences. The steps disclosed herein are based on cDNA libraries but equally apply to genomic DNA libraries.

This new method utilizes PCR kits which enable the researcher to amplify long pieces of DNA. The XL-PCR amplification kit 20 (Perkin-Elmer) was employed. However, equivalent products may be available from other major suppliers. This novel method allows one person to process multiple genes (up to 96 genes) at a time and obtain extended or complete sequence (possibly full-length) of the cDNAs of interest within 6-10 days. This compares very favorably 25 with current competitive methods like screening with labelled probes which allow one worker to process only about 3-5 genes and obtain initial results in 14-40 days. This represents an increase in throughput of at least 1000%.

This increased efficiency is possible because of the 30 inventive combination of steps shown in the flow chart (Figure 1). First, primer design and synthesis (based on a known partial sequence) can be performed in about two days. The PCR amplification can be performed in 6-8 hours. Multiple libraries

can be pooled and therefore screened at the same time. The next steps of purification and ligation take about one day. Then transformation and growing up the bacteria take one day. Then screening for clones with additional sequence of the genes of interest by PCR takes approximately five hours. The next steps of DNA preparation and sequencing of the selected clones can be performed in about one day. This totals 6-7 days. At the end of this time, one has usually obtained a much longer cDNA sequence, assuming such a longer cDNA existed in the libraries than what was initially sequenced. If the new sequence is a complete gene, then the goal has been reached. If the complete sequence has not been obtained, one still has a much longer sequence than before, and this longer sequence can be used to design primers to repeat the procedure on the same or another library. The choice of library is up to the researcher, but a preferred library is one that has been size-selected to include only larger cDNAs.

This method presumes that one already has partial cDNA sequences, either from a publicly available database or the scientist's own earlier research, including but not limited to earlier preparation of a cDNA library whose cDNAs have been partially sequenced. The cDNA library may have been prepared with oligo dT or random primers. The difference between oligo dT and randomly primed libraries is that a randomly primed library will have more sequences which contain 5' ends of cDNAs. A randomly primed library may be particularly useful for further work when the oligo dT library does not yield a complete gene. Random priming of the library also helps yield more cDNA sequences of different lengths. Library preparation techniques which promote longer insert sizes will in turn permit the sequencing of more complete cDNAs. Obviously, the larger the protein, the less likely it is that the complete cDNA will be found in a single plasmid.

Figure 2 shows a typical plasmid containing a cDNA which had

been partially sequenced from the 5' end with T3 as a primer. The top darkened portion represents the insert containing the gene of interest.

5 Step 1: PCR-amplification of cDNA-clones containing the gene of interest

The first step of this method requires the design of two primers based on the known sequence. The known sequence can be obtained by those skilled in the art either by a wet lab method or from the many publicly available DNA databases. One primer is 10 synthesized to be extended in an antisense direction (XLR) and the other in the sense direction (XLS or XLF). In effect, the primers are designed to anneal to either end of the known sequence and to be extended "outward" from there to generate amplicons containing new, unknown sequences of the genes of interest. This is 15 different from typical PCR, in which the primers are designed to amplify a known sequence in a direction "inward" toward each other.

The primers need to be designed in a way displaying optimal criteria for extra long PCR. A program like Oligo 4.0s (National 20 Biosciences, Inc., Plymouth MN) can be employed for this purpose. In general primers should be 22-30 nucleotides in length, consist of a GC content of 50% or more and anneal at 68°C-72°C to the target. Hairpin structures and primer-primer dimerizations must be avoided.

25 Primers varying from the conditions described above may result in amplification of the desired targets providing extension conditions have been adjusted.

Figure 3 shows the next step, in which a cDNA library is used as a template and the two primers (XLR and XLS) amplify plasmids 30 containing the gene of interest. In this step, it is very helpful to use PCR enzymes which provide high fidelity and copy long sequences, such as that provided in the XL-PCR kit (Part No. N808-0182, Perkin Elmer, Applied Biosystems, Foster City, CA).

Generally, kit instructions should be followed, including suggestions to optimize concentrations of various reagents. In the examples disclosed *infra*, 25pMol of each primer worked well. Template (plasmid library) concentrations can be varied (see Examples *infra* for details). It is essential to thoroughly resuspend the enzyme in solution prior to use, especially if the solution has been stored at -20°C. If the enzyme is not adequately resuspended, its effectiveness is impaired. The preferred system is setup initially in two layers, employing Ampliwax® PCR Gems. However, efficiency can be increased by avoiding the use of these Gems and initiating amplification by using the "hot-start" technique by adding Magnesium, which is essential for amplification, at 82° C.

Although various cycling conditions are detailed in the examples *infra*, the following cycling conditions have been found to be optimal with the MJ PCT200 thermocycler (MJ Research, Watertown, MA). Times and temperatures may be varied to optimize conditions in different thermocyclers.

Step 1 94° for 60 sec (initial denaturation)
20 Step 2 94° for 15 sec
Step 3 65° for 1 min
Step 4 68° for 7 min
Step 5 Repeat step 2-4 for 15 additional times
Step 6 94° for 15 sec
25 Step 7 65° for 1 min
Step 8 68° for 7 min + 15 sec/cycle
Step 9 Repeat step 6-8 for 11 additional times
Step 10 72° for 8 min
Step 11 4° for 0.00 sec (to hold at 4°)

30 At the end of these 28 cycles, 50 µl of the reaction mix is removed; on the remaining reaction mix, an additional 10 additional cycles are run, as outlined below:

Step 1 94° for 15 sec
35 Step 2 65° for 1 min
Step 3 68° for (10 min + 15 sec)/cycle
Step 4 Repeat step 1-3 for 9 additional times
Step 5 72° for 10 min

Next a 5-10 μ l aliquot of the reaction mixture can be analyzed on a mini-gel to determine which reactions were successful.

Step 2: Purification of amplicons containing the gene of interest

5 Figure 4 is a graphical representation of the amplified cDNA segments which have been separated on an agarose gel. Note that there are a variety of lengths of cDNA. Although the rest of the method could be performed using all extended cDNA species, the method can proceed optionally after selecting the largest products
10 (likeliest to provide the remainder of the full-length gene). Some of the larger species may in fact be hybrid clones which contain two cDNA inserts as a result of malfunction during the cDNA library construction which may represent an incomplete digestion with the restriction enzyme at the end of the cDNA
15 synthesis. Such amplified hybrid clones, also called chimera, could result in overlooking the correct targeted extensions.

Successful reaction products should be purified on an agarose gel (preferentially low agarose concentrations 0.6-0.8% should be used) or other appropriate method. An appropriate volume of
20 reaction mixture should be loaded to obtain good separation of the products and to separate them from the plasmid library (template) still in the reaction mixture. Contamination with the template cDNA library will result in transformants which don't contain the desired gene and will require an extensive screening of many
25 colonies. The bands representing the genes of interest are then cut out of the gel and purified using a method like the QIAQuick gel extraction kit (Qiagen, Inc., Chatsworth, CA).

Step 3: Cloning of amplicons containing the gene of interest

30 Eventual overhangs are converted into blunt ends to facilitate religation and cloning of the products. For this purpose, Klenow enzyme (3 units/reaction mixture) and dNTP's (0.2 mM final concentration) are added and the reaction is incubated at room temperature for 30 min. The Klenow enzyme is then

inactivated by incubating the reaction at 75° for 15 min.

The products are then ethanol precipitated and redissolved in 13 μ l of ligation buffer containing 1 mM ATP. 1ml T4-DNA ligase (15 units) and T4 Polynucleotide kinase (5 units) are added and the reaction is incubated at room temperature for 2-3 hours or 5 overnight at 16°C.

3 μ l of the ligation mixture are transformed into 40ml of competent E.coli cells (prepared with a standard protocol). 80 μ l of SOC medium are added and after 1 hour of recovery of the cells 10 at 37°C the whole transformation mixture is plated on LB-agar 2XCarb-containing petri plates.

Step 4: Screening of cloned products

The next day 8 or 12 colonies are randomly picked from each plate and grown in individual wells of a sterile 96-well 15 microtiter plate (e.g. 96 Well Cell Culture Cluster, Catalog No. 3799, Costar Corp., Cambridge, MA 02140). Each well contains 150ml of LB/2XCarb medium. Thus, each row of the microtiter plate contains twelve clones from the same extension reaction. The cells are grown over night at 37°C.

20 The next day, 5 μ l of these overnight cultures are transferred into a non-sterile 96-well plate (Falcon 3911 Microtest III™, Flexible Assay Plate, Becton Dickinson, Oxnard, CA) and diluted 1:10 with water. 5 μ l of each dilution are then transferred into a PCR array (e.g., Cycleplate, Robbins Scientific Corp., Sunnyvale, 25 CA). To obtain a 1X final concentration of PCR reagents, 15 μ l of a 1.33X concentrated PCR mix are added to each well. Another way of efficient screening for extension products is the multiplex PCR method where multiple specific primers are pooled and submitted to the same reaction, therefore increasing the efficiency of setting 30 up the screening mixtures. Addition of the PCR-template (individual cultures) has been improved by the use of a 96-pin tool with which an aliquot of all 96 cultures grown as described

above can be transferred into the PCR-screening mix in a matter of 1-2 minutes.

For PCR amplification, the final concentrations are 1X for PCR mix, 5 μ M of each of a vector primer and one or both of the gene specific primers used for the original extension reaction and 0.75 units of Taq polymerase are added to each well.

5 Amplification generally was performed using the following conditions:

Step 1 94°C for 60sec

10 Step 2 94°C for 20sec

Step 3 55°C for 30sec

Step 4 72°C for 90sec

Step 5 repeat steps 2-4 for an additional 29 times

Step 6 72°C for 180sec

15 Step 7 4°C for ever

Aliquots of these PCR reactions are run on agarose gels together with molecular weight markers. The size of the resulting PCR products will allow direct determination of how much additional sequence the selected clones contain compared to the 20 original partial cDNA. The efficiency of the method has been further improved by using the resulting PCR-products directly for sequencing thus avoiding the necessity of preparing plasmids.

The appropriate clones are selected and grown for plasmid preparation and sequencing.

25 Plasmid preparations are made with standard kits familiar to those skilled in the art. Examples include the PROMEGA Magic MINIPREP and the AGTC alkaline lysis kit.

30 Sequencing is performed employing standard automated ABI sequencing equipment and protocols using either dye-primer or dye-terminator kits.

Sequence processing and assemblage of the sequencing data are performed using standard ABI software, including INHERIT™ analysis and the Power assembler.

INDUSTRIAL APPLICABILITY

Example 1

For the initial method evaluation, a known gene was selected. A partial sequence of the human 90-kDa heat-shock protein gene (HUMHSP90, accession M16660) had been identified in a THP-1 library. This partial sequence (Incyte clone T-014201) initiated at base 1127 of the sequence with accession number M16660.

1.1 Primer design

Two primers were designed to perform the method described in the invention.

10 Primer 1 (XLR) 5' AGC TGT CCA TGA TGA ACA CAC G 3'
(1180-1159)

Primer 2 (XLS) 5' AAT AGG CAC CAC ACC AAC TGA G 3'
(2011-2032)

15 1.2 Template preparation

A THP-1 cDNA library constructed into the LambdaZAP vector (Stratagene) was converted into a plasmid library following the mass excision protocol. Plasmids of the excised libraries were prepared using the Quiagen Midi plasmid purification kit.

20 1.3 XL-PCR reaction set-up

The extension reactions were prepared following the instructions provided with the GeneAmp XL PCR Kit (Part No. N808-0182) from Perkin Elmer. A two layer system was set up as follows:

25 The lower reagent mix was prepared by pipetting the following components into a 0.2ml MicroAmp reaction tube.

Lower reagent mix preparation:

Water	13.6 μ l
3.3X buffer	12.0 μ l
dATP (10mM)	2.0 μ l
dCTP (10mM)	2.0 μ l

dGTP	(10mM)	2.0 μ l
dTTP	(10mM)	2.0 μ l
Primer XLS	(50 μ M)	1.0 μ l
Primer XLR	(50 μ M)	1.0 μ l
5	Mg (OAc) 2 (25mM)	4.4 μ l

Total lower reagent mix 40.0 μ l

10 One AmpliWax™ gem was added to the tube. The wax was melted by incubating the reaction tubes at 75°C for 5 minutes. Then the tubes were cooled down to 4°C.

Upper reagent mix preparation:

3.3X buffer	18.0 ml
15 rTth DNA Polymerase	2.0 ml

Total upper enzyme mix 20.0 μ l

20 20 μ l of the enzyme/buffer mix are added to each tube and kept separated from the lower mix by the wax layer.

Addition of template:

The template DNA (excised library) was diluted to an appropriate concentration in water and then added to the upper mix. Mixing of the components is not necessary.

25 Template (6.25ng/ml) 40.0 μ l

Final volume 100.0 μ l

30 1.4 XL-PCR amplification

For amplification the following protocol was employed:

Step 1 94° for 60 sec (initial denaturation)
Step 2 94° for 15 sec
Step 3 65° for 1 min
Step 4 68° for 7 min
5 Step 5 Repeat step 2-4 for 15 additional times
Step 6 94° for 15 sec
Step 7 65° for 1 min
Step 8 68° for 7 min + 15 sec/cycle
Step 9 Repeat step 6-8 for 11 additional times
10 Step 10 72° for 8 min
Step 11 4° for 0.00 sec (to hold at 4°)

1.5 Purification of amplified products

30 μ l of the amplified products were run on a 0.7% agarose
15 gel for 16 hours. Visible DNA bands were then cut out and purified
using the QIAquick gel purification kit.

1.6 Cloning of amplified products

Klenow enzyme (3 units/reaction) and dNTP's (0.2mM final
concentration) were added and the reactions were incubated at room
20 temperature for 30 min followed by incubation at 75° C for 15 min.
The products were then ethanol precipitated and redissolved in 13
 μ l of ligation buffer containing 1mM ATP. T4-DNA ligase (15 units)
and T4 Polynucleotide kinase (5 units) were added, and the
reaction was incubated at room temperature for 3 hours.

25 3 μ l of the ligation mixture were transformed into 40 ml of
competent E.coli cells. After heatshocking the cells at 42° C for
45 seconds, 80 μ l of SOC medium were added, and the cells were
allowed to recover at 37° C for 1 hour. The whole transformation
mixture then was plated on LB-agar/2XCarb-containing petri dish
30 plates.

1.7 Screening of cloned products

The next day 10 colonies were randomly picked and grown

overnight in Falcon 2059 tubes (Becton Dickinson, Oxnard, CA) containing 3 ml of LB-broth with 2X Carb.

5 $5 \mu\text{l}$ of the cultures were diluted 1:10 with water and 5 ml of this dilution were transferred into MicroAmpTM PCR tubes (Perkin Elmer, Applied Biosystems, Foster City, CA).

15 $15 \mu\text{l}$ of a 1.33X concentrated PCR mix were added to each well.

The 1.33 x concentrated PCR mix contained the following components:

10	10X PCR-buffer	2.0 μl
	2mM dNTPs	2.0 μl
	M13 rev primer (0.01mM)	1.0 μl
	Primer 2 (XLR, 0.01mM)	1.0 μl
	Taq Polymerase	0.15 μl
15	Water	8.85 μl

Final Volume	15.0 μl
--------------	--------------------

The PCR cycling conditions were choosen as follows:

Step 1 94° C for 60sec
20 Step 2 94° C for 20sec
Step 3 55° C for 30sec
Step 4 72° C for 90sec
Step 5 repeat steps 2-4 for an additional 29 times
Step 6 72° C for 180 sec
25 Step 7 4° C for ever

Aliquots of the amplified products were run on a 0.8% agarose gel in parallel with the 1 kb DNA ladder (Life Technologies, Gaithersburg, MD 20897). Appropriate plasmids containing different size inserts were selected for sequencing analysis.

30 1.8 Sequencing analyis of cloned products

The DNA of the selected clones was prepared using the

Wizard™ Minipreps DNA Purification System (Promega Corporation, Madison, WI) following the instructions of the manufacturer. Sequencing reactions were performed using the PRISM™ Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Part No 401628, 5 Perkin Elmer, Applied Biosystems, Foster City, CA).

1.9 Analysis of sequenced products

Three clones were selected for sequencing (14201.3, 14201.5, 14201.13). The sequences obtained (SEQ ID NOS:3-5, respectively) were aligned using the DNASIS Multiple sequence alignment program.

10 Clone 14201.3 initiated at base 24 of the published sequence (HUMHSP90), clone 14201.5 initiated at base 13 of the published sequence and clone 14201.13 initiated at base 538 of the published sequence, the original clone (14201) initiated at base 1127 of the published sequence.

15 Figure 7A-7H shows an alignment of the obtained sequences with the published human Hsp 90 nucleotide sequence. Clones 14201.3 and 14201.5 contain part of the 5' untranslated region and therefore the full coding region of the gene has been obtained.

Example 2

20 For further method evaluation, a second known gene was selected. A partial sequence from a liver library was found to be related to that of the human cathepsin B gene (accession L16510, HUMCATHB, SEQ ID NO:6). This partial sequence (Incyte clone 87058, SEQ ID NO:7) initiated at base 1066 of the sequence with 25 accession number L16510.

2.1 Primer design

Two primers were designed to perform the method described in the invention:

Primer 1 (XLR) 5' AAG CCA TTG TCA CCC CAG TCA G 3'
30 (1103-1082)

Primer 2 (XLS) 5' GGT TCA CTG TGG AAT CGA ATC 3'
(1125-1145)

2.2 Template preparation

A liver cDNA library constructed into the LambdaZAP vector (Stratagene) was converted into a plasmid library following the mass excision protocol. Plasmids of the excised libraries were prepared using the Quiagen Midi plasmid purification kit.

5 2.3 XL-PCR reaction set-up

The extension reactions were prepared following the instructions provided with the GeneAmp XL PCR Kit (Part No. N808-0182) from Perkin Elmer. A two layer system was set up as described below. The lower reagent mix was prepared by pipetting 10 the following components into a 0.2ml MicroAmp reaction tube.

Lower reagent mix preparation:

Water		13.6 μ l
3.3 x buffer		12.0 μ l
dATP	(10mM)	2.0 μ l
15 dCTP	(10mM)	2.0 μ l
dGTP	(10mM)	2.0 μ l
dTTP	(10mM)	2.0 μ l
Primer XLS	(50 μ M)	1.0 μ l
Primer XLR	(50 μ M)	1.0 μ l
20 Mg (OAc) 2	(25 μ M)	4.4 μ l
<hr/>		
Total lower reagent mix		40.0 μ l

One AmpliWax® gem was added to the tube. This was melted by 25 incubating the reaction tubes at 75°C for 5 minutes. Then the tubes were cooled down to 4°C.

Upper reagent mix preparation:

3.3X buffer		18.0 μ l
30 rTth DNA Polymerase		2.0 μ l

Total	upper enzyme mix	20.0 μ l
-------	------------------	--------------

20 μ l of the enzyme/buffer mix were added to each tube and kept separated from the lower mix by the wax layer.

5 Addition of template:

The template DNA (excised library) was diluted to an appropriate concentration in water and then added to the upper mix. Mixing of the components is not necessary.

Template (6.25ng/ μ l)	40.0 μ l
----------------------------	--------------

10

Final volume	100.0 μ l
--------------	---------------

2.4 XL-PCR amplification

For amplification the following protocol was employed:

Step 1 94° for 60 sec (initial denaturation)

15 Step 2 94° for 15 sec

Step 3 65° for 1 min

Step 4 68° for 7 min

Step 5 Repeat step 2-4 for 15 additional times

Step 6 94° for 15 sec

20 Step 7 65° for 1 min

Step 8 68° for 7 min + 15 sec/cycle

Step 9 Repeat step 6-8 for 11 additional times

Step 10 72° for 8 min

Step 11 4° for 0.00 sec (to hold at 4°)

25 2.5 Purification of amplified products

30 30 μ l of the amplified products were run on a 0.7% agarose gel for 16 hours. Visible DNA bands were then cut out and purified using the QIAQuick gel purification kit.

2.6 Cloning of amplified products

35 Klenow enzyme (3 units/reaction) and dNTP's (0.2mM final concentration) were added, and the reactions were incubated at room temperature for 30 min followed by incubation at 75°C for 15

min.

The products were then ethanol precipitated and redissolved in 13 µl of ligation buffer containing 1mM ATP. T4-DNA ligase (15 units) and T4 Polynucleotide kinase (5 units) were added, and the 5 reaction was incubated at room temperature for 3 hours.

3 µl of the ligation mixture were transformed into 40 µl of competent E.coli cells. After heatshocking the cells at 42°C for 45 seconds, 80 µl of SOC medium were added; and the cells were allowed to recover at 37°C for 1 hour. The whole transformation mixture then was plated on LB-agar 2x Carb-containing petri dishes.

2.7 Screening of cloned products

The next day 10 colonies were randomly picked and grown overnight in Falcon 2059 tubes (Becton Dickinson, Oxnard, CA 15 93030) containing 3 ml of LB-broth with 2X Carb.

5 µl of the cultures were diluted 1:10 with water and 5 µl of this dilution were transferred into MicroAmp™ PCR tubes (Perkin Elmer, Applied Biosystems, Foster City, CA).

15 µl of a 1.33 x concentrated PCR mix were added to each 20 tube.

The 1.33 x concentrated PCR mix contained the following components:

10 x PCR-buffer	2.0 µl
2mM dNTPs	2.0 µl
25 M13 rev primer (0.01mM)	1.0 µl
Primer 2 (XLR, 0.01mM)	1.0 µl
Taq Polymerase	0.15 µl
water	8.85 µl

30 Final Volume	15.0 µl
-----------------	---------

The PCR cycling conditions were as follows:

Step 1 94°C for 60sec
Step 2 94°C for 20sec
Step 3 55°C for 30sec
Step 4 72°C for 90sec
5 Step 5 repeat steps 2-4 for an additional 29 times
Step 6 72°C for 180sec
Step 7 4°C for ever

Aliquots of the amplified products were run on a 0.8% agarose gel in parallel with the 1kb DNA ladder (Life Technologies, 10 Gaithersburg, MD 20897). Appropriate clones containing different size inserts were selected for sequencing analysis.

2.8 Sequencing analysis of cloned products

The DNA of the selected clones was prepared using the Wizard™ Minipreps DNA Purification System (Promega Corporation, 15 Madison, WI) following the instructions of the manufacturer.

Sequencing reactions were performed using the PRISM™ Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Part No 401628, Perkin Elmer, Applied Biosystems, Foster City, CA).

2.9 Analysis of sequenced products

20 Three clones were selected for sequencing (87058.6, 87058.8, 87058.16). The sequences obtained (SEQ ID NOS:8-10, respectively) were aligned using the DNASIS Multiple sequence alignment program and are shown in Figures 8A through 8F. Clone 87058.6 initiated at base 644 of the published sequence (HUMCATHB, SEQ ID NO:6), 25 clone 87058.8 initiated at base 353 of the published sequence and clone 87058.16 initiated at base 58 of the published sequence, the original clone (87058, SEQ ID NO:7) initiated at base 1058 of the published sequence.

Figures 8A through 8F show an alignment of the obtained 30 sequences with the published human Hsp 90 nucleotide sequence. Clone 87058.16 contains part of the 5'UT and therefore the full coding region of the gene.

Example 3

In Example 3, a full length cDNA (Seq ID NO 11) of a novel P2U purinergic receptor homolog was obtained by the inventive method and is the subject of U.S. Patent Application 08/459,046 filed June 2, 1995, which is hereby incorporated by reference.

5 Inherit™ and BLAST search and alignment tools were used to relate a partial sequence found in Incyte Clone 179696 from the placental cDNA library to the GenBank sequence of RNU09402, a G-protein coupled surface receptor from rat (Rice WR et al (1995) Am J Respir Cell Molec Biol 12:27-32).

10 The cDNA of Incyte 179696 was extended to full length using a modified XL-PCR (Perkin Elmer) procedure. Primers were designed based on known sequence; one primer was synthesized to initiate extension in the antisense direction (XLR) and the other to extend sequence in the sense direction (XLF). The primers allowed the 15 sequence to be extended "outward" from the known sequence, thus generating amplicons containing new, unknown nucleotide sequence comprising the gene of interest. The primers were designed using Oligo 4.0 (National Biosciences Inc, Plymouth MN) to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to 20 anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

25 The cDNA library was used as a template, and XLR (bases 278-298) and XLF (bases 587-610) primers were used to extend and amplify the 179696 sequence. By following the instructions for the XL-PCR kit and thoroughly mixing the enzyme, high fidelity amplification is obtained. Beginning with 25 pMol of each primer and the recommended concentrations of all other components of the 30 kit, PCR was performed using the MJ PTC200 thermocycler (MJ Research, Watertown MA) and the following parameters:

- Step 1 94° C for 60 sec (initial denaturation)
- Step 2 94° C for 15 sec
- Step 3 65° C for 1 min

Step 4 68° C for 7 min
Step 5 Repeat step 2-4 for 15 additional cycles
Step 6 94° C for 15 sec
Step 7 65° C for 1 min
5 Step 8 68° C for 7 min + 15 sec/cycle
Step 9 Repeat step 6-8 for 11 additional cycles
Step 10 72° C for 8 min
Step 11 4° C (and holding)

At the end of 28 cycles, 50 μ l of the reaction mix was
10 removed; and the remaining reaction mix was run for an additional
10 cycles as outlined below:

Step 1 94° C for 15 sec
Step 2 65° C for 1 min
Step 3 68° C for (10 min + 15 sec)/cycle
15 Step 4 Repeat step 1-3 for 9 additional cycles
Step 5 72° C for 10 min

A 5-10 μ l aliquot of the reaction mixture was analyzed by
electrophoresis on a low concentration (about 0.6-0.8%) agarose
mini-gel to determine which reactions were successful in extending
20 the sequence. Although all extensions potentially contain a full
length gene, some of the largest products or bands were selected
and cut out of the gel. Further purification involved using a
commercial gel extraction method such as QIAQuick™ (QIAGEN Inc,
Chatsworth CA). After recovery of the DNA, Klenow enzyme was used
25 to trim single-stranded, nucleotide overhangs creating blunt ends
which facilitated religation and cloning.

After ethanol precipitation, the products were redissolved in
13 μ l of ligation buffer. Then, 1 μ l T4-DNA ligase (15 units) and
1 μ l T4 polynucleotide kinase were added, and the mixture was
30 incubated at room temperature for 2-3 hours or overnight at 16° C.
Competent *E. coli* cells (in 40 μ l of appropriate media) were
transformed with 3 μ l of ligation mixture and cultured in 80 μ l of
SOC medium (Sambrook J et al, supra). After incubation for one

hour at 37° C, the whole transformation mixture was plated on Luria Broth (LB)-agar (Sambrook J et al, *supra*) containing carbenicillin at 25 mg/L. The following day, 12 colonies were randomly picked from each plate and cultured in 150 µl of liquid LB/carbenicillin medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 µl of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 µl of each sample was transferred into a PCR array.

For PCR amplification, 15 µl of concentrated PCR reaction mix (1.33X) containing 0.75 units of Taq polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
Step 6	72° C for 180 sec
Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid and sequenced.

Example 4

In this example, the inventive method was used to obtain a novel full length cDNA from the partial sequence found in Incyte clone 08118 which was found to be somewhat homologous to the GenBank sequence of C5a anaphylatoxin receptor, a G-protein coupled surface receptor from dog (Perret J et al (1995) Biochem

J 288:911-17). Based on the partial cDNA sequence, primers (XLR = GAAAGACAGCCACCACCAACG and XLF = AGAAAGCAAGGCAGTCCATTCAAGG) were designed. Essentially the same method outlined in Example 3 above was used to extend the partial sequence of 8118 to obtain 5 the full length sequence (Seq ID NO:12) of a novel C5a-like receptor homolog which is the subject of a U.S. Patent Application 08/462,355 filed June 5, 1995, and whose disclosure is incorporated by reference.

While the present invention has been described with reference 10 to specific enzymes and sequences, particularly PCR enzyme, and formulations containing such, those skilled in the art understand that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to 15 adapt a particular situation, material, enzyme, process, process step or steps and still carry out the objective, spirit and scope of the invention. All such modifications are intended to be within the scope of the claims appended hereto.

20

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: INCYTE PHARMACEUTICALS, INC.

(ii) TITLE OF INVENTION: IMPROVED METHOD FOR OBTAINING
FULL LENGTH cDNA SEQUENCES

(iii) NUMBER OF SEQUENCES: 12

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: INCYTE PHARMACEUTICALS, INC.
(B) STREET: 3330 Hillview Avenue
(C) CITY: Palo Alto
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94304

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To Be Assigned
(B) FILING DATE: Filed Herewith

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/487,112
(B) FILING DATE: 7-JUN-1995

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/462,355
(B) FILING DATE: 5-JUN-1995

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/459,046
(B) FILING DATE: 2-JUN-1995

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 08/566,334
(B) FILING DATE: 1-DEC-1995

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION SERIAL NO: US 60/006,809
(B) FILING DATE: 15-NOV-1995

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Luther, Barbara J.
(B) REGISTRATION NUMBER: 33954
(C) REFERENCE/DOCKET NUMBER: HP-001-1 PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415-855-0555

(B) TELEFAX: 415-852-0195

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2543 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank HUMHSP90
- (B) CLONE: Accession No. M16660

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTCCGGCGCA	GTGTTGGGAC	TGTCTGGGTA	TCGGAAAGCA	AGCCTACGTT	GCTCACTATT	60
ACGTATAATC	CTTTTCTTTT	CAAGATGCCT	GAGGAAGTGC	ACCATGGAGA	GGAGGGAGGTG	120
GAGACTTTG	CCTTCAGGC	AGAAATTGCC	CAAATCATGT	CCCTCATCAT	CAATACCTTC	180
TATTCCAACA	AGGAGATTTT	CCTTCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCTTGGAC	240
AAGATTGCT	ATGAGAGCCT	GACAGACCCCT	TCGAAGTTGG	ACAGTGGTAA	AGAGCTGAAA	300
ATTGACATCA	TCCCCAACCC	TCAGGAACGT	ACCCCTGACTT	TGGTAGACAC	AGGCATTGGC	360
ATGACCAAAG	CTGATCTCAT	AAATAATTG	GGAACCATTG	CCAAGTCTGG	TACTAAAGCA	420
TTCATGGAGG	CTCTTCAGGC	TGGTGCAGAC	ATCTCCATGA	TTGGGCAGTT	TGGTGTGGC	480
TTTTATTCTG	CCTACTTGGT	GGCAGAGAAA	GTGGTTGTGA	TCAGAAAGCA	CAACGATGAT	540
GAACAGTATG	CTTGGGAGTC	TTCTGCTGGA	GGTCCCTCA	CTGTGCGTGC	TGACCATGGT	600
GAGCCCATTG	GCATGGGTAC	CAAAGTGATC	CTCCATCTTA	AAGAAGATCA	GACAGAGTAC	660
CTAGAAAGAGA	GGCGGGTCAA	AGAAGTAGTG	AAGAACATT	CTCAGTTCAT	AGGCTATCCC	720
ATCACCCCTT	ATTTGGAGAA	GGAACGAGAG	AAGGAAATTA	GTGATGATGA	GGCAGAGGAA	780
GAGAAAGGTG	AGAAAGAAGA	GGAAGATAAA	GATGATGAAG	AAAAGCCAA	GATCGAAGAT	840
GTGGGTTCA	ATGAGGAGGA	TGACAGCGGT	AAGGATAAGA	AGAAGAAAAC	TAAGAAGATC	900
AAAGAGAAAT	ACATTGATCA	GGAAGAACTA	AACAAGACCA	AGCCTATTTG	GACCAGAAC	960
CCTGATGACA	TCACCCAAGA	GGAGTATGGA	GAATTCTACA	AGAGCCTCAC	TAATGACTGG	1020
GAAGACCACT	TGGCAGTCAA	GCACCTTTCT	GTAGAAGGTC	AGTTGGAATT	CAGGGCATTG	1080
CTATTTATTC	CTCGTCGGGC	TCCCTTTGAC	CTTTTTGAGA	ACAAGAAGAA	AAAGAACAAAC	1140
ATCAAACCTCT	ATGTCCGCCG	TGTGTTCATC	ATGGACAGCT	GTGATGAGTT	GATACCAGAG	1200

TATCTCAATT TTATCCGTGG TGTGGTTGAC TCTGAGGATC TGCCCCTGAA CATCTCCCGA	1260
GAAATGCTCC AGCAGAGCAA AATCTTGAAA GTCATTGCA AAAACATTGT TAAGAAGTGC	1320
CTTGAGCTCT TCTCTGAGCT GGCAGAAGAC AAGGAGAATT ACAAGAAATT CTATGAGGCA	1380
TTCTCTAAAA ATCTCAAGCT TGGAATCCAC GAAGACTCCA CTAACCGCCG CCGCCTGTCT	1440
GAGCTGCTGC GCTATCATACT CTCAGCTCT GGAGATGAGA TGACATCTCT GTCAGAGTAT	1500
GTTTCTCGCA TGAAGGAGAC ACAGAAGTCC ATCTATTACA TCACTGGTGA GAGCAAAGAG	1560
CAGGTGGCCA ACTCAGCTTT TGTGGAGCGA GTGCGGAAAC GGGGCTTCGA GGTGGTATAT	1620
ATGACCGAGC CCATTGACGA GTACTGTGTG CAGCAGCTCA AGGAATTGTA TGGGAAGAGC	1680
CTGGTCTCAG TTACCAAGGA GGGTCTGGAG CTGCCTGAGG ATGAGGAGGA GAAGAAGAAG	1740
ATGGAAGAGA GCAAGGCAAA GTTGAGAAC CTCTGCAAGC TCATGAAAGA AATCTTAGAT	1800
AAGAAGGTTG AGAAGGTGAC AATCTCCAAT AGACTTGTGT CTTCACCTTG CTGCATTGTG	1860
ACCAAGCACCT ACGGCTGGAC AGCCAATATG GAGCGGATCA TGAAAGCCCCA GGCACCTCGG	1920
GACAACCTCCA CCATGGGCTA TATGATGGCC AAAAAGCACC TGGAGATCAA CCCTGACCAC	1980
CCCATTTGTGG AGACGCTGCG GCAGAAGGCT GAGGCCGACA AGAATGATAA GGCAGTTAAG	2040
GACCTGGTGG TGCTGCTGTT TGAAACCGCC CTGCTATCTT CTGGCTTTTC CCTTGAGGAT	2100
CCCCAGACCC ACTCCAACCG CATCTATCGC ATGATCAAGC TAGGTCTAGG TATTGATGAA	2160
GATGAAGTGG CAGCAGAGGA ACCCAATGCT GCAGTTCTG ATGAGATCCC CCCTCTCGAG	2220
GGCGATGAGG ATGCGCTCG CATGGAAGAA GTCGATTAGG TTAGGAGTTC ATAGTTGGAA	2280
AACTTGTGCC CTTGTATAGT GTCCCCATGG GCTCCCACTG CAGCCTCGAG TGCCCCCTGTC	2340
CCACCTGGCT CCCCCCTGCTG GTGTCTAGTG TTTTTTTCCC TCTCCTGTCC TTGTGTTGAA	2400
GGCAGTAAAC TAAGGGTGTC AAGCCCCATT CCCTCTCTAC TCTTGACAGC AGGATTGGAT	2460
GTTGTGTATT GTGGTTTATT TTATTTCTT CATTGTTGTC TGAAATTAAA GTATGCAAAA	2520
TAAAGAATAT GCCGTTTTA TAC	2543

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 261 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: THP-1
 (B) CLONE: 14201

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AAGAAAAAGA ACAACATCAA ACTCTATGTC CGCCGTGTGT TCATCATGGC AGCTGTGATG	60
AGTTGATACC AGAGTATCTC AATTTTATCC GTGGTGTGGT TGACTTGAGG TCTGCCCTG	120
AACATCTCCC GGAAATGCTC CAGCAGAGCA AAATCTTGAA AGGCATTCCG AAAAACATTG	180
TTAAGAGTGC CTTAGCTCTT CTCTAGCTGG CAGAAGCAAG GGGATTTCAA GAAATTCTTT	240
TGGGGGGATT TCTTAAAAAT T	261

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 478 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: THP-1
 (B) CLONE: 14201.3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCTGGGTATC GGAAAGCAAG CCTACGTTGC TCACTATTAC GTATAATCCT TTTCTTCAG	60
ATGCCTGAGG AAGTGCACCA TGGAGAGGAG GAGGTGGAGA CTTTGCCTT TCAGGCAGAA	120
ATTGCCAAC TCATGTCCCT CATCATCAAT ACCTCCTATT CCAACAAGGA GATTTCCTCG	180
GGAGTTGATC TCTAATGCTT CTGATGCCTC GGACAAGATT CGCTATGAAG CCTGACAGAC	240
CCTTCGAAGT GGTCAAGCGGC AAGAGCTGAA AATTGACATC ATCCCCAACC CTCAGGAACG	300
TCCCTGTACT TTGGGTAGAC ACAGGCATTG GCATAAACAA AGCTGACCTC ATATTATTG	360
GGGAACCATT GCCAAGTCTT GTCTAAAAGC ATTCAATGGAG GCTCTCAGGT TGGCGCAGAC	420
ATCTCCAGAT TGGCAGGTGG GTGTTGGCTT TATTCTGCCC ACTTGGTGGC AGAGAAAT	478

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 508 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: THP-1
 (B) CLONE: 14201.5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTGAGAGTAT	60
TCTGGGTATC	
GGAAAGCAAG	
CCTACGTTGC	
TCACTATTAC	
GTATAATCCT	
TTTCTTTCA	120
AGATGCCTGA	
GGAAGTGCAC	
CATGGAGAGG	
AGGAGGTGGA	
GACTTTGCC	
TTTCAGGCAG	180
AAATTGCCCA	
ACTCATGTCC	
CTCATCATCA	
ATACCTCCTA	
TTCCAACAAG	
GAGATTTCC	240
TTCGGGAGTT	
GATCTCTAAT	
GCTTCTGATG	
CCTTGGACAA	
GATTGCTAT	
GAGAGCCTGA	300
CAGACCCCTTC	
GAAGTTGGAC	
AGTGGTAAAG	
AGCTGAAAAT	
TGACATCATC	
CCCAACCCCTC	360
AGGAACGTAC	
CCTGACTTTG	
GGTAGACACA	
GGCATCGGCA	
TGACCAAAAG	
CTGATCTCAT	420
AATAATTGGG	
AACCATTGCA	
AGTCTGGTAC	
TAAAGCATTC	
ATGGAGGGCTC	
TTCAGGCTGG	480
TGCAGACATC	
TCCATGATTG	
GGCAGCTTGG	
GTGTTGCTTT	
ATTCTGCCTC	
CTTGGTGGCA	508
GAGAAAGTGT	
TGTGATCA	

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 547 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: THP-1
 (B) CLONE: 14201.13

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTGAGAGTAT	60
GTCGAGTTAC	
TGTGGAGGTT	
CCTTCACTGC	
GTGCTGACAT	
GGTGAGCCCA	
TGGGAGCGGT	120
ACCAAGTGAT	
CCTCCATCTC	
AAAGAAGATC	
AGACAGAGTA	
CCTAGAGAGA	
GGCGGATCAA	180
AGAGTAGTGA	
TGAGCATCCT	
CAGATCATAG	
GCTATCCCCT	
CACCCTTTTT	
TGGAGAAGGA	240
CGAGAGAAGG	
AATTAGGATG	
ATGAGGCAGA	
GGAAGAGAAT	
GGTGAGAATG	
AAGAGGAGTA	300
ACGATGATGA	
AGAAACCCCA	
AGATCGATGA	
TGTGGTTCA	
ATGAGGGGAT	
GACAGCGGTA	360
GATAAGAAGA	
AGAAACTAGA	
ATCATCGGAT	
CATGACAGGA	
AGAAACTAAC	
GATCATCTTT	420
CGGCCAGAAT	
CCCTGATGTC	
ATCACCCAAG	
AGGGTATGGA	
GATTCTACA	
TGCAGCTCAC	480
TTTACTGGGC	
AAGACACTTG	
GCAGCAACAC	
TTTTCTGTAG	
AAGGCCATTG	

CATCACGCAT TGCTATTCTT CCCTCGCCGT CTCCTTGAC CTGGTCTGGC ATCATGGTGT	540
CTTGATC	547

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1996 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank HUMCATHB
- (B) CLONE: Accession No. L16510

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TCCGGCAACG CCAACCGCTC CGCTGCGCGC AGGCTGGCT GCAGGCTCTC GGCTGCAGCG	60
CTGGGCTGGT GTGCAGTGGT GCGACCACGG CTCACGGCAG CCTCAGGCCAC CCAGATGTAA	120
GCGATCTGGT TCCCACCTCA GCCTCCCGAG TAGTGGATCT AGGATCCGGC TTCCAACATG	180
TGGCAGCTCT GGGCCTCCCT CTGCTGCCTG CTGGTGTGG CCAATGCCCG GAGCAGGCC	240
TCTTCCATC CCCTGTCGGA TGAGCTGGTC AACTATGTCA ACAAACGGAA TACCACGTGG	300
CAGGCCGGGC ACAACTTCTA CAACGTGGAC ATGAGCTACT TGAAGAGGCT ATGTGGTACC	360
TTCCCTGGGTG GGCCCAAGGCC ACCCCAGAGA GTTATGTTTA CCGAGGACCT GAAGCTGCCT	420
GCAAGCTTCG ATGCACGGGA ACAATGGCCA CAGTGTCCCA CCATCAAAGA GATCAGAGAC	480
CAGGGCTCCT GTGGCTCCTG CTGGGCCTTC GGGGCTGTGG AAGCCATCTC TGACCGGATC	540
TGCATCCACA CCAATGCGCA CGTCAGCGTG GAGGTGTCGG CGGAGGACCT GTCACATGC	600
TGTGGCAGCA TGTGTGGGA CGGCTGTAAT GGTGGCTATC CTGCTGAAGC TTGGAACCTTC	660
TGGACAAGAA AAGGCCTGGT TTCTGGTGGC CTCTATGAAT CCCATGTAGG GTGCAGACCG	720
TACTCCATCC CTCCCTGTGA GCACCACGTC AACGGCTCCC GGCCCCCATG CACGGGGAG	780
GGAGATAACCC CCAAGTGTAG CAAGATCTGT GAGCCTGGCT ACAGCCCGAC CTACAAACAG	840
GACAAGCACT ACGGATAACAA TTCCTACAGC GTCTCCAATA GCGAGAAGGA CATCATGGCC	900
GAGATCTACA AAAACGGCCC CGTGGAGGGA GCTTTCTCTG TGTATTGGA CTTCTGCTC	960
TACAAGTCAG GAGTGTACCA ACACGTCACC GGAGAGATGA TGGGTGGCCA TGCCATCCGC	1020
ATCCTGGGCT GGGGAGTGGA GAATGGCACA CCCTACTGGC TGGTTGCCAA CTCCTGGAAC	1080
ACTGACTGGG GTGACAATGG CTTCTTTAAA ATACTCAGAG GACAGGATCA CTGTGGAATC	1140

GAATCAGAAG TGGTGGCTGG AATTCCACGC ACCGATCAGT ACTGGGAAAA GATCTAATCT	1200
GCCGTGGGCC TGTCGTGCCA GTCCTGGGG CGAGATCGGG GTAGAAATGC ATTTTATTCT	1260
TTAAGTTCAC GTAAGATACA AGTTTCAGGC AGGGTCTGAA GGACTGGATT GGCCAAACAT	1320
CAGACCTGTC TTCCAAGGAG ACCAAGTCCT GGCTACATCC CAGCCTGTGG TTACAGTGCA	1380
GACAGGCCAT GTGAGCCACC GCTGCCAGCA CAGAGCGTCC TTCCCCCTGT AGACTAGTGC	1440
CGTGGGAGTA CCTGCTGCC AGCTGCTGTG GCCCCCTCCG TGATCCATCC ATCTCCAGGG	1500
AGCAAGACAG AGACGCAGGA TGGAAAGCGG AGTTCCTAAC AGGATGAAAG TTCCCCCATC	1560
AGTTCCCCA GTACCTCCAA GCAAGTAGCT TTCCACATTT GTCACAGAAA TCAGAGGAGA	1620
GATGGTGTG GGAGCCCTT GGAGAACGCC AGTCTCCAGG TCCCCCTGCA TCTATCGAGT	1680
TTGCAATGTC ACAACCTCTC TGATCTTGTG CTCAGCATGA TTCTTTAATA GAAGTTTTAT	1740
TTTCGTGCA CTCTGCTAAT CATGTGGGTG AGCCAGTGGG ACAGCGGGAG CCTGTGCTGG	1800
TTTGCAGATT GCCTCTAAT GACGCGGCTC AAAAGGAAAC CAAGTGGTCA GGAGTTGTTT	1860
CTGACCCACT GATCTCTACT ACCACAAGGA AAATAGTTA GGAGAAACCA GCTTTACTG	1920
TTTTGAAAAA ATTACAGCTT CACCTGTCA AGTTAACAAAG GAATGCCTGT GCCAATAAAA	1980
GGTTTCTCCA ACTTGAA	1996

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 294 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: LIVER
- (B) CLONE: 87058

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGGCACGAGC CAACTCCTGG AACACTGACT GGGGTGACAA TGGCTTCTTT AAAATACTCA	60
GAGGACAGGT TCACTGTGGA ATCGAATCAG AAGTGGTGGC TGGAATTCCA CGCACCGTTC	120
AGTACTGGGA AAAGTCTAAT CTGCCGTGGG CCTTCGTGCC AGTCCTGGGG GCGAGATGGG	180
GGTAGAAATG CATTATTC TTTAAGTTCA CGTAAGATAC AAGTTTCAGA CAGGGGTCTA	240
AGGCCTGGTT GCCAAATCA GACCTGTTT TCAAGGGGCC CAAGTCCTGG GTTC	294

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 552 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: Liver
 (B) CLONE: 87058.6

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GTGAAGCTTG GAACTTCTGG ACAAGAAAAG GCCTGGTTTC TGGTGGCCTC TATGAATCCC	60
ATGTAGGGTG CAGACCGTAC TCCATCCCTC CCTGTGAGCA CCACGTCAAC GGCTCCCGGC	120
CCCCATGCAC GGGGGAGGGA GATACCCCCA AGTGTAGCAA GATCTGTGAG CCTGGCTACA	180
GCCCGACCTA CAAACAGGAC AAGCACTACG GATACAATTG CTACAGCGTC TCCAATAGCG	240
AGAAGGACAT CATGGCCGAG ATCTACAAAA ACGGCCCCGT GGAGGGAGCT TTCTCTGTGT	300
ATTCGGACTT CCTGCTCTAC AAGTCAGGAG TGTACCAACA CGTCACCGGA GAGATGATGG	360
GTGGCCATGC CATCCGCATC CTGGGCTGGG GAGTGGAGAA TGGCACAAACC TACTGGCTGG	420
TTGGCAACTC CTGGAACACT GACTGGGGTG ACAATGGGTT CACTGTGGAA TCGAATCAGA	480
ACTGGTGGTG GAATTCCACG CACGATCAAG TGCTGGAAA AGATCTTAAT CTGCCGGGGC	540
TGTGGCCAG TC	552

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 559 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: Liver
 (B) CLONE: 87058.8

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAGGTACCTT CCTGGGTGGG CCCAAGCCAC CCCAGAGAGT TATGTTTACC GAGGACCTGA	60
AGCTGCCTGC AAGCTTCGAT GCACGGGAAC AATGCCACA GTGTCCCACC ATCAAAGAGA	120
TCAGAGACCA GGGTCCTGTG GCTCCTGCTG GGCCTTCGGG GCTGTGGAAG CCATCTCTGA	180

CCGGATCTGA TCCACACCAA TGCACACGTC AGCGTGGAGG TGTGGCGGA GGACTGCTCA	240
CATGCTGTGG CAGATGTGTG GGGACGGCTG TAATGGTGGC TATCCTGCTG AAGCTTGGAC	300
TTCTGGACAA GAAAAGGCC C TGGTTCTGG TGGCCTCTAT GATCCCATGT AGGGTGTAGA	360
CCGTACTCCA TCCCTCCCTG TGAAGCACCA CGTCAACGGT TCCCAGGCC CATGCACGGG	420
GAGGGAGATA CCCCCAAGTG TAACAAGATC TGTGAGCCTG GGTACAGTCC CGACCACAAA	480
CAGGAAAAGC ACTACGGATA CAATTCCCTCA GGTCTCCAAT AGTGAGAAGG GACATCATGC	540
CGAGATCTAC AATAACGGC	559

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 622 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: Liver
- (B) CLONE: 87058.16

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGTTGAGAT TCGGACAGTC CGAAAACGTC CGGCAAGTCA CCCGCTCCGC TGGCGCAGGC	60
TGGGTGCAGG CTCTCGGTGC AGGCTGGGTG GATCTAGGAT CCGGCTTCCA ACATGTGGCA	120
GTTCTGGGCC TCCCTCTGTG CCTGCTGGTG TTGGACAATG CCCGGAGGAG GCCTCTTTCC	180
ATCCCCCTGTC GGATGAGCTG GTCACTATGT CAACAAACGG AATACCACGT GGAGGCCGGG	240
AACAACTTCT ACAACGTGGA CATGAGCTAC TTGAGAGGTA TGTGGTACCT TCCTGGGTGG	300
GCCCAAGCCA CCCCAGAGAG TTTGTTTACC GAGGACCTGA GCTGCCTGCA AGCTTCGAAG	360
GACGGGAACA ATGGCCACAG TGTCCCACCA TCAAAGAGAT CAGAGACAGG GCTCCTGTGG	420
TCCTGCTGGG CCTCCGGGGC TGTGGAAGCA TCTCTGACCG GATCTGCATC CACACCAATG	480
GCACGTCAGC GTGGTGGTGT CGGGGAGGAC CTGATCACCT TTGTGGTAGC ATGTGTGGGG	540
GACGGCTGTA ATGGTGGTTA TCCTGTGAAG CTGGGCCTTC TAGAAAGAAA AGGCTGTTTT	600
GGTGGCCTTA TGACTCCCAT GT	622

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 984 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: Placenta
- (B) CLONE: 179696

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGGAATGGG ACAATGGCAC AGACCAGGCT CTGGGCTTGC CACCCACCAC CTGTGTCTAC	60
CGCGAGAACT TCAAGCAACT GCTGCTCCCA CCTGTGTATT CGGCGGTGCT GGCGCCTGCC	120
CTCCCGCTGA ACATCTGTGT CATTACCCAG ATCTGCACGT CCCGCCGGGC CCTGACCCGC	180
ACGGCCGTGT ACACCCCTAAA CCTTGCTCTG CCTGACCTGC TATATGCCTG CTCCCTGCC	240
CTGCTCATCT ACAACTATGC CCAAGGTGAT CACTGGCCCT TTGGCGACTT CGCCTGCC	300
CTGGTCCGCT TCCTCTTCTA TGCCAACCTG CACGGGAGGA TCCTCTTCCT CACCTGCATC	360
AGCTTCCAGC GCTACCTGGG CATCTGCCAC CCGCTGGCCC CCTGGCACAA ACGTGGGGC	420
CGCCGGGCTG CCTGGCTAGT GTGTGTAGCC GTGTGGCTGG CCGTGACAAC CCAGTGCCTG	480
CCACAGCCA TCTTCGCTGC CACAGGCATC CAGCGTAACC GCACTGTCTG TTATGACCTC	540
AGCCCGCCTG CCCTGGCCAC CCACTATATG CCCTATGGGA TGGCTCTCAC TGTACATCGC	600
TTCCCTGCTGC CCTTTGCTGC CCTGCTGGCC TGCTACTGTC TCCTGGCCTG CCGCCTGTGC	660
CGCCAGGATG GCCCGGCAGA GCCTGTGGCC CAGGAGCGGC GTGGCAAGGC GGCCCGCATG	720
GCCGTGGTGG TGGCTGCTGT CTTTGGCATC AGCTTCTGC CTTTCACAT CACCAAGACA	780
GCCTACCTGG CAGTGCCTC GACGCCGGC GTCCCCTGCA CTGTATTGGA GGCCCTTGCA	840
GCGGCCTACA AAGGCACGCG GCCGTTGCC AGTGCCAAC ACGTGCTGGA CCCCACCTC	900
TTCTACTTCA CCCAGAAGAA GTTCCGCCGG CGACCACATG AGCTCCTACA GAAACTCACA	960
GACAAATGGC AGAGGCAGGG TCGC	984

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1446 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Mast Cell
 (B) CLONE: 8118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATGGCGTCTT	TCTCTGCTGA	GACCAATTCA	ACTGACCTAC	TCTCACAGCC	ATGGAATGAG	60
CCCCCAGTAA	TTCTCTCCAT	GGTCATTCTC	AGCCTTACTT	TTTTACTGGG	ATTGCCAGGC	120
AATGGGCTGG	TGCTGTGGGT	GGCTGGCCTG	AAGATGCAGC	GGACAGTGAA	CACAATTTGG	180
TTCCTCCACC	TCACCTTGGC	GGACCTCCTC	TGCTGCCTCT	CCTTGGCCTT	CTCGCTGGCT	240
CACTTGGCTC	TCCAGGGACA	GTGGCCCTAC	GGCAGGTTCC	TATGCAAGCT	CATCCCCCTCC	300
ATCATTGTCC	TCAACATGTT	TGGCAGTGTC	TTCCCTGCTTA	CTGCCATTAG	CCTGGATCGC	360
TGTCTTGTGG	TATTCAAGCC	AATCTGGTGT	CAGAACATCATC	GCAATGTAGG	GATGGCCTGC	420
TCTATCTGTG	GATGTATCTG	GGTGGTGGCT	TTTGTGTTGT	GCATTCCCTGT	GTTCGTGTAC	480
CGGGAAATCT	TCACTACAGA	CAACCATAAT	AGATGTGGCT	ACAAATTTGG	TCTCTCCAGC	540
TCATTAGATT	ATCCAGACTT	TTATGGGGAT	CCACTAGAAA	ACAGGTCTCT	TGAAAACATT	600
GTTCAGCCGC	CTGGAGAAAT	GAATGATAGG	TTAGATCCTT	CCTCTTTCCA	AACAAATGAT	660
CATCCTTGGA	CAGTCCCCAC	TGTCTTCCAA	CCTCAAACAT	TTCAAAGACC	TTCTGCAGAT	720
TCACTCCCTA	GGGGTTCTGC	TAGGTTAACCA	AGTCAAAATC	TGTATTCTAA	TGTATTTAAA	780
CCTGCTGATG	TGGTCTCAC	TAAAATCCCC	AGTGGGTTTC	CTATTGAAGA	TCACGAAACC	840
AGCCCACCTGG	ATAACTCTGA	TGCTTTCTC	TCTACTCATT	TAAAGCTGTT	CCCTAGCGCT	900
TCTAGCAATT	CCTTCTACGA	GTCTGAGCTA	CCACAAGGTT	TCCAGGATTA	TTACAATTAA	960
GGCCAATTCA	CAGATGACGA	TCAAGTGCCA	ACACCCCTCG	TGGCAATAAC	GATCACTAGG	1020
CTAGTGGTGG	GTTCCTTGCT	GCCCTCTGTT	ATCATGATAG	CCTGTTACAG	CTTCATTGTC	1080
TTCCGAATGC	AAAGGGGCCG	CTTCGCCAAG	TCTCAGAGCA	AAACCTTTCG	AGTGGCCGTG	1140
GTGGTGGTGG	CTGTCTTCT	TGTCTGCTGG	ACTCCATACC	ACATTTGGGG	AGTCCTGTCA	1200
TTGCTTACTG	ACCCAGAAAC	TCCCTGGGG	AAAACCTCTGA	TGTCCTGGGA	TCATGTATGC	1260
ATTGCTCTAG	CATCTGCCAA	TAGTTGCTTT	AATCCCTTCC	TTTATGCCCT	CTTGGGGAAA	1320
GATTTTAGGA	AGAAAGCAAG	GCAGTCCATT	CAGGAAATTC	TGGAGGCAGC	CTTCAGTGAG	1380
GAGCTCACAC	GTTCCACCCA	CTGTCCCTCA	AACAATGTCA	TTTCAGAAAG	AAATAGTACA	1440
ACTGTG						1446

CLAIMS

1. A method of extending the sequence of a partial complementary DNA (cDNA) using polymerase chain reaction (PCR), comprising the steps of:

5 a) combining a first and second PCR primer with nucleic acid from a cDNA library expected to contain said partial cDNA, or a genomic library, under conditions suitable for synthesis of nucleic acid PCR products from the first and second primers, wherein said first and second primers are capable of annealing to 10 opposite strands of the partial cDNA or genomic DNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA polymerase in an antisense direction and the second primer is capable of being extended in a sense direction.

15 b) purifying the PCR products, and
 c) identifying extended nucleotide sequences derived from said partial cDNA or said genomic DNA.

2. The method of Claim 1 wherein identifying extended sequences comprises nucleic acid sequencing.

20 3. The method of Claim 2 further comprising extending the nucleotide sequences of step 6c by repeating steps 6a through 6c on the nucleotide sequences identified in step 6c.

4. A method of extending the nucleotide sequence of a partial complementary DNA (cDNA) using polymerase chain reaction (PCR), comprising the steps of:

25 a) combining a first and second PCR primer with nucleic acid from a cDNA library expected to contain said partial cDNA, or a genomic library, under conditions suitable for synthesis of nucleic acid PCR products from the first and second primers, wherein said first and second primers are capable of annealing to 30 opposite strands of the partial cDNA or genomic DNA and initiating nucleic acid synthesis in an outward manner and wherein the first primer is capable of being extended by DNA polymerase in an

antisense direction and the second primer is capable of being extended in a sense direction.


- b) purifying the PCR products,
- c) ligating the purified PCR products under conditions suitable for the formation of circular closed nucleic acid,
- 5 d) transforming a host cell with the circular closed nucleic acid and culturing the transformed host cell under conditions suitable for growth,
- e) recovering said circular closed nucleic acid from the 10 cultured, transformed host cell,
- f) identifying extended nucleotide sequences derived from said partial cDNA or said genomic DNA.

5. The method of Claim 4 wherein identifying extended sequences comprises nucleic acid sequencing.


15 6. The method of Claim 4 wherein culturing the transformed host cell under conditions suitable for growth comprises culturing in the presence of selective antibiotic conditions.

7. The method of Claim 4 wherein said host cell is E.coli.


8. The method of Claim 4 wherein after step 4b and prior to step 20 4c, the purified PCR products are treated under conditions suitable for converting nucleic acid overhangs to blunt ends.

**FIGURE 1**

2/20

**FIGURE 2**

3/20

**FIGURE 3**

4/20






FIGURE 4

5/20

**FIGURE 5**

6/20

**FIGURE 6**

7/20

	10	20	30	40	50	
Hsp 90	1 CTCGGCGCA	GTGTTGGAC	TGTCTGGTA	TCGGAAAGCA	AGCCTACGTT	50
14201	1 -----	-----	-----	-----	-----	50
14201.3	1 -----	-----	-----gCTGGGTA	TCGGAAAGCA	AGCCTACGTT	50
14201.5	1 -----	-----GTGTTGGAC	TGTCTGGTA	TCGGAAAGCA	AGCCTACGTT	50
14201.13	1 -----	-----	-----	-----	-----	50
	60	70	80	90	100	
Hsp 90	51 GCTCACTATT	ACGTATAATC	CTTTTCTTTT	CAAGATGCCT	GAGGAAGTGC	100
14201	51 -----	-----	-----	-----	-----	100
14201.3	51 GCTCACTATT	ACGTATAATC	CTTTTCTNTN	CAAGATGCCT	GAGGAAGTGC	100
14201.5	51 GCTCACTATT	ACGTATAATC	CTTTTCTTTT	CAAGATGCCT	GAGGAAGTGC	100
14201.13	51 -----	-----	-----	-----	-----	100
	110	120	130	140	150	
Hsp 90	101 ACCATGGAGA	GGAGGGAGGTG	GAGACTTTTG	CCTTCAGGC	AGAAATTGCC	150
14201	101 -----	-----	-----	-----	-----	150
14201.3	101 ACCATGGAGA	GGAGGGAGGTG	GAGACTTTTG	CCTTCAGGC	AGAAATTGCC	150
14201.5	101 ACCATGGAGA	GGAGGGAGGTG	GAGACTTTTG	CCTTCAGGC	AGAAATTGCC	150
14201.13	101 -----	-----	-----	-----	-----	150
	160	170	180	190	200	
Hsp 90	151 CAACTCATGT	CCCTCATCAT	CAATACCTTC	TATTCCAACA	AGGAGATT	200
14201	151 -----	-----	-----	-----	-----	200
14201.3	151 CAACTCATGT	CCCTCATCAT	CAATACCTCC	TATTCCAACA	AGGAGATT	200
14201.5	151 CAACTCATGT	CCCTCATCAT	CAATACCTCC	TATTCCAACA	AGGAGATT	200
14201.13	151 -----	-----	-----	-----	-----	200
	210	220	230	240	250	
Hsp 90	201 CCTTCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCCTGGAC	AAGATTCCGT	250
14201	201 -----	-----	-----	-----	-----	250
14201.3	201 CCTTCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCCTGGAC	AAGATTCCGT	250
14201.5	201 CCTTCGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCCCTGGAC	AAGATTCCGT	250
14201.13	201 -----	-----	-----	-----	-----	250
	260	270	280	290	300	
Hsp 90	251 ATGAGAGCCT	GACAGACCCCT	TCGAAGTTGG	ACAGTGGTAA	AGAGCTGAAA	300
14201	251 -----	-----	-----	-----	-----	300
14201.3	251 ATGAGAGCCT	GACAGACCCCT	TCGAAGTTGG	TCAGCGGCAA	NGAGCTGAAA	300
14201.5	251 ATGAGAGCCT	GACAGACCCCT	TCGAAGTTGG	ACAGTGGTAA	AGAGCTGAAA	300
14201.13	251 -----	-----	-----	-----	-----	300

FIGURE 7A

8/20

Hsp 90	310	320	330	340	350	
14201	301	-----	-----	-----	-----	350
14201.3	301	ATTGACATCA	TCCCCAACCC	TCAGGAACGT	ACCCCTGACTT	TGGTAGACAC
14201.5	301	ATTGACATCA	TCCCCAACCC	TCAGGAACGT	NCCCTGACTT	TGGTAGACAC
14201.13	301	ATTGACATCA	TCCCCAACCC	TCAGGAACGT	ACCCCTGACTT	TGGTAGACAC
	350	350	350	350	350	
	360	370	380	390	400	
Hsp 90	351	AGGCATTGGC	ATGACCAAAG	CTGATCTCAT	AAaTAATTtG	GGAACCATTG
14201	351	-----	-----	-----	-----	400
14201.3	351	AGGCATTGGC	ATGAAacAAG	CTGAcCTCAT	NA _n TTATTcG	GGgAaCcATt
14201.5	351	AGGCATcGGC	ATGACCAAAG	CTGATCTCAT	AA _n TAATTnG	GGAACCATTG
14201.13	351	-----	-----	-----	-----	400
	400	400	400	400	400	
	410	420	430	440	450	
Hsp 90	401	CCAAGTCTGG	TACTAAAGCA	TTCATGGAGG	CTCTTCAGGC	TGGTGCAGAC
14201	401	-----	-----	-----	-----	450
14201.3	401	CCAAGTCTTG	TNCTAAAGCA	TTCATGGAGG	CTCTNCAGGN	TGGcGCAGAC
14201.5	401	NCAAGTCTGG	TACTAAAGCA	TTCATGGAGG	CTCTTCAGGC	TGGTGCAGAC
14201.13	401	-----	-----	-----	-----	450
	450	450	450	450	450	
	460	470	480	490	500	
Hsp 90	451	ATCTCCATGA	TTGGGCAGTT	tGGTGTGAGC	TttTATTCTG	CCTACTTGCT
14201	451	-----	-----	-----	-----	500
14201.3	451	ATCTCCANGA	TTNGGCAGNT	GGGTGTGAGC	TTnTATTCTG	CC _c ACTTGCT
14201.5	451	ATCTCCATGA	TTGGGCAGTT	GGGTGTGAGC	TTnTATTCTG	CC _c TCTTGCT
14201.13	451	-----	-----	-----	-----	500
	500	500	500	500	500	
	510	520	530	540	550	
Hsp 90	501	GGCAGAGAAA	GTGGTTGTGA	TCAGAAAGCA	CAACGATGAT	GAacAGTATG
14201	501	-----	-----	-----	-----	550
14201.3	501	GGCAGAGAAA	NNT	-----	-----	550
14201.5	501	GGCAGAGAAA	GTNGTTGTGA	TCA	-----	550
14201.13	501	-----	-----	-----	TT	GAGnAGTATG
	550	550	550	550	550	
	560	570	580	590	600	
Hsp 90	551	cTtgGgAGTc	TtCTGcTGGA	GGTTCCCTCA	CTgtGCGTGC	TGACcATGGT
14201	551	-----	-----	-----	-----	600
14201.3	551	-----	-----	-----	-----	600
14201.5	551	-----	-----	-----	-----	600
14201.13	551	-TcnGnAGT-	TaCTGnTGGA	GGTTCCCTCA	CTnnGCGTGC	TGAC-ATGGT
	600	600	600	600	600	
	610	620	630	640	650	
Hsp 90	601	GAGCCCATTG	GcAtgGGTAC	CAaAGTGATC	CTCCATCTtA	AAGAAGATCA
14201	601	-----	-----	-----	-----	650
14201.3	601	-----	-----	-----	-----	650
14201.5	601	-----	-----	-----	-----	650
14201.13	601	GAGCCCATTG	GgA _g ggGGTAC	CA _n AGTGATC	CTCCATCTCA	AAGAAGATCA
	650	650	650	650	650	

FIGURE 7B

9/20

		660	670	680	690	700	
Hsp 90	651	GACAGAGTAC	CTAGAaGAGA	GGCGGgTCAA	AGaAGTAGTG	AaGAaGCATT	700
14201	651	-----	-----	-----	-----	-----	700
14201.3	651	700
14201.5	651	700
14201.13	651	GACAGAGTAC	CTAGAnGAGA	GGCGGgTCAA	AGnAGTAGTG	AtGAAnGCATc	700
		710	720	730	740	750	
Hsp 90	701	CTCAGtTCAT	AGGCTATCCC	ATCACCCCTT	aTTTGGAGAA	GGaACGAGAG	750
14201	701	-----	-----	-----	-----	-----	750
14201.3	701	750
14201.5	701	750
14201.13	701	CTCAGAaTCAT	AGGCTATCCC	ATCACCCCTT	nTTTGGAGAA	GGnACGAGAG	750
		760	770	780	790	800	
Hsp 90	751	AAGGAaATTA	GtGATGATGA	GGCAGAGGAA	GAGAAaGGTG	AGAAaGAAGA	800
14201	751	-----	-----	-----	-----	-----	800
14201.3	751	800
14201.5	751	800
14201.13	751	AAGGAAnATTA	GnGATGATGA	GGCAGAGGAA	GAGAAtGGTG	AGAAtGAAGA	800
		810	820	830	840	850	
Hsp 90	801	GGAAaGaTAAa	GATGATGAAG	AAAgCCCAA	GATCGAaGAT	GTGGgITTCAG	850
14201	801	-----	-----	-----	-----	-----	850
14201.3	801	850
14201.5	801	850
14201.13	801	GGAnGnTAAc	GATGATGAAG	AAAnCCCAA	GATCGATGAT	GTGGnITTCAG	850
		860	870	880	890	900	
Hsp 90	851	ATGAGGAGGA	TGACAGCGGT	aAgGATAAGA	AGAAGAAaAC	TAaGAagATC	900
14201	851	-----	-----	-----	-----	-----	900
14201.3	851	900
14201.5	851	900
14201.13	851	ATGAGGnGGA	TGACAGCGGT	nAnGATAAGA	AGAAGAAaAC	TAnGAnnATC	900
		910	920	930	940	950	
Hsp 90	901	AAAGAGAAAT	ACATTGATCA	GGAAAGAACTA	AACAAGACCA	AGCCTATTG	950
14201	901	-----	-----	-----	-----	-----	950
14201.3	901	950
14201.5	901	950
14201.13	901	950
		960	970	980	990	1000	
Hsp 90	951	GACCAGAAAC	CCTGATGACA	TCACCCAAAGA	GGAGTATGGA	GAATTCTACA	1000
14201	951	-----	-----	-----	-----	-----	1000
14201.3	951	1000
14201.5	951	1000
14201.13	951	1000

FIGURE 7C

10/20

Hsp 90	1010	1020	1030	1040	1050	
14201	1001 AGAGCCCTCAC	TAATGACTGG	GAAGACCAC	TGGCAGTC	AA	GCAC
14201.3	1001	-----	-----	-----	-----	1050
14201.5	1001	1050
14201.13	1001	1050
Hsp 90	1060	1070	1080	1090	1100	
14201	1051 GTAGAAGGTC	AGTTGGAATT	CAGGGCATTG	CTATTTATTC	CTCGTCGGGC	1100
14201.3	1051	-----	-----	-----	-----	1100
14201.5	1051	1100
14201.13	1051	1100
Hsp 90	1110	1120	1130	1140	1150	
14201	1101 TCCCCTTGAC	CTTTTGAGA	ACAAGAAGAA	AAAGAACAAAC	ATCAAAC	CT
14201.3	1101	-----	-----	-----	-----	1150
14201.5	1101	1150
14201.13	1101	1150
Hsp 90	1160	1170	1180	1190	1200	
14201	1151 ATGTCCGCCG	TGTGTTCATC	ATGGaCAGCT	GTGATGAGTT	GATACCAGAG	1200
14201.3	1151 ATGTCCGCCG	TGTGTTCATC	ATGGnCAGCT	GTGATGAGTT	GATACCAGAG	1200
14201.5	1151	1200
14201.13	1151	1200
Hsp 90	1210	1220	1230	1240	1250	
14201	1201 TATCTCAATT	TTATCCGTGG	TGTGGTTGAC	TcTGAGGAGTC	TGCCCTTGAA	1250
14201.3	1201 TATCTCAATT	TTATCCGTGG	TGTGGTTGAC	TnTGAGGnTC	TGCCCTTGAA	1250
14201.5	1201	1250
14201.13	1201	1250
Hsp 90	1260	1270	1280	1290	1300	
14201	1251 CATCTCCCGa	GAAATGCTCC	AGCAGAGCAA	AATCTTGAAA	GtCATTGCGA	1300
14201.3	1251 CATCTCCCGn	GAAATGCTCC	AGCAGAGCAA	AATCTTGAAA	GgCATTGCGA	1300
14201.5	1251	1300
14201.13	1251	1300
Hsp 90	1310	1320	1330	1340	1350	
14201	1301 AAAACATTGT	TAAGaAGTGC	CTTgAGCTCT	TCTCTgAGCT	GGCAGAAC	1350
14201.3	1301 AAAACATTGT	TAAGnAGTGC	CTTnAGCTCT	TCTCTnAGCT	GGCAGAACnC	1350
14201.5	1301	1350
14201.13	1301	1350

FIGURE 7D

11/20

	1360	1370	1380	1390	1400	
Hsp 90	1351 AAGGAGAATT	ACAAGAAATT	CTATGAGGCA	TTCTCTAAAA	ATCTCAAGCT	1400
14201	1351 AAGG-GGATT	TCAAGAAATT	CTTTGGGG--	-----	-----	1400
14201.3	1351	1400
14201.5	1351	1400
14201.13	1351	1400
	1410	1420	1430	1440	1450	
Hsp 90	1401 TGGAATCCAC	GAAGACTCCA	CTAACCGCCG	CCGCCTGTCT	GAGCTGCTGC	1450
14201	1401 -----	-----	-----	-----	-----	1450
14201.3	1401	1450
14201.5	1401	1450
14201.13	1401	1450
	1460	1470	1480	1490	1500	
Hsp 90	1451 GCTATCATAC	CTCCCAGTCT	GGAGATGAGA	TGACATCTCT	GTCAGAGTAT	1500
14201	1451 -----	-----	-----	-----	-----	1500
14201.3	1451	1500
14201.5	1451	1500
14201.13	1451	1500
	1510	1520	1530	1540	1550	
Hsp 90	1501 GTTTCTCGCA	TGAAGGAGAC	ACAGAAGTCC	ATCTATTACA	TCACTGGTGA	1550
14201	1501 -----	-----	-----	-----	-----	1550
14201.3	1501	1550
14201.5	1501	1550
14201.13	1501	1550
	1560	1570	1580	1590	1600	
Hsp 90	1551 GAGCAAAGAG	CAGGTGGCCA	ACTCAGCTTT	TGTGGAGCGA	GTGCGGAAAC	1600
14201	1551 -----	-----	-----	-----	-----	1600
14201.3	1551	1600
14201.5	1551	1600
14201.13	1551	1600
	1610	1620	1630	1640	1650	
Hsp 90	1601 GGGGCTTCGA	GGTGGTATAT	ATGACCGAGC	CCATTGACGA	GTACTGTGTG	1650
14201	1601 -----	-----	-----	-----	-----	1650
14201.3	1601	1650
14201.5	1601	1650
14201.13	1601	1650

FIGURE 7E

12/20

	1660	1670	1680	1690	1700	
Hsp 90	1651 CAGCAGCTCA	AGGAATTGAG	TGGGAAGAGC	CTGGTCTCAG	TTACCAAGGA	1700
14201	1651	-----	-----	-----	-----	1700
14201.3	1651	1700
14201.5	1651	1700
14201.13	1651	1700
	1710	1720	1730	1740	1750	
Hsp 90	1701 GGGTCTGGAG	CTGCCTGAGG	ATGAGGGAGGA	GAAGAAGAAAG	ATGGAAGAGA	1750
14201	1701	-----	-----	-----	-----	1750
14201.3	1701	1750
14201.5	1701	1750
14201.13	1701	1750
	1760	1770	1780	1790	1800	
Hsp 90	1751 GCAAGGCAAA	GTTTGAGAAC	CTCTGCAAGC	TCATGAAAGA	AATCTTAGAT	1800
14201	1751	1800
14201.3	1751	1800
14201.5	1751	1800
14201.13	1751	1800
	1810	1820	1830	1840	1850	
Hsp 90	1801 AAGAAGGTG	AGAAGGTGAC	AATCTCCAAT	AGACTTGTGT	CTTCACCTTG	1850
14201	1801	1850
14201.3	1801	1850
14201.5	1801	1850
14201.13	1801	1850
	1860	1870	1880	1890	1900	
Hsp 90	1851 CTGCATTGTG	ACCAGCACCT	ACGGCTGGAC	AGCCAAATATG	GAGCGGATCA	1900
14201	1851	1900
14201.3	1851	1900
14201.5	1851	1900
14201.13	1851	1900
	1910	1920	1930	1940	1950	
Hsp 90	1901 TGAAAGCCCA	GGCACCTCGG	GACAACCTCA	CCATGGGCTA	TATGATGGCC	1950
14201	1901	1950
14201.3	1901	1950
14201.5	1901	1950
14201.13	1901	1950
	1960	1970	1980	1990	2000	
Hsp 90	1951 AAAAAGCACC	TGGAGATCAA	CCCTGACCAC	CCCATTGTGG	AGACGCTGCG	2000
14201	1951	2000
14201.3	1951	2000
14201.5	1951	2000
14201.13	1951	2000

FIGURE 7F

13/20

		2010	2020	2030	2040	2050	
Hsp 90	2001	GCAGAAGGCT	GAGGCCGACA	AGAATGATAA	GGCAGTTAAG	GACCTGGTGG	2050
14201	2001	2050
14201.3	2001	2050
14201.5	2001	2050
14201.13	2001	2050
		2060	2070	2080	2090	2100	
Hsp 90	2051	TGCTGCTGTT	TGAAACCGCC	CTGCTATCTT	CTGGCTTTTC	CCTTGAGGAT	2100
14201	2051	2100
14201.3	2051	2100
14201.5	2051	2100
14201.13	2051	2100
		2110	2120	2130	2140	2150	
Hsp 90	2101	CCCCAGACCC	ACTCCAACCG	CATCTATCGC	ATGATCAAGC	TAGGTCTAGG	2150
14201	2101	2150
14201.3	2101	2150
14201.5	2101	2150
14201.13	2101	2150
		2160	2170	2180	2190	2200	
Hsp 90	2151	TATTGATGAA	GATGAAGTGG	CAGCAGAGGA	ACCCAATGCT	GCAGTTCCCTG	2200
14201	2151	2200
14201.3	2151	2200
14201.5	2151	2200
14201.13	2151	2200
		2210	2220	2230	2240	2250	
Hsp 90	2201	ATGAGATCCC	CCCTCTCGAG	GGCGATGAGG	ATGCGTCTCG	CATGGAAGAA	2250
14201	2201	2250
14201.3	2201	2250
14201.5	2201	2250
14201.13	2201	2250
		2260	2270	2280	2290	2300	
Hsp 90	2251	GTCGATTAGG	TTAGGAGTTC	ATAGTTGGAA	AACCTGTGCC	CTTGTATAGT	2300
14201	2251	2300
14201.3	2251	2300
14201.5	2251	2300
14201.13	2251	2300
		2310	2320	2330	2340	2350	
Hsp 90	2301	GTCCCCATGG	GCTCCCCTG	CAGCCTCGAG	TGCCCCCTGTC	CCACCTGGCT	2350
14201	2301	2350
14201.3	2301	2350
14201.5	2301	2350
14201.13	2301	2350

FIGURE 7G

	2360	2370	2380	2390	2400	
Hsp 90	2351	CCCCCTGCTG	GTGTCTAGTG	TTTTTTCCC	TCTCCTGTCC	TTGTGTTGAA
14201	2351	2400
14201.3	2351	2400
14201.5	2351	2400
14201.13	2351	2400
	2410	2420	2430	2440	2450	
Hsp 90	2401	GGCAGTAAAC	TAAGGGTGTC	AAGCCCCATT	CCCTCTCTAC	TCTTGACAGC
14201	2401	2450
14201.3	2401	2450
14201.5	2401	2450
14201.13	2401	2450
	2460	2470	2480	2490	2500	
Hsp 90	2451	AGGATTGGAT	GTTGTGTATT	GTGGTTTATT	TTATTTTCTT	CATTTTGTTC
14201	2451	2500
14201.3	2451	2500
14201.5	2451	2500
14201.13	2451	2500
	2510	2520	2530	2540	2550	
Hsp 90	2501	TGAAATTAAA	GTATGCAAAA	TAAAGAATAT	GCCGTTTTTA	TAC.....
14201	2501	2550
14201.3	2501	2550
14201.5	2501	2550
14201.13	2501	2550

○

FIGURE 7H

15/20

caphepsin	1	10	20	30	40	50	
87058	1	-----	-----	-----	-----	-----	50
87058.6	1	-----	-----	-----	-----	-----	50
87058.8	1	-----	-----	-----	-----	-----	50
87058.16	1	-----	-----	-----	-----	-----	50
		60	70	80	90	100	
caphepsin	51	GGCTGCAGCG	CTGGGCTGGT	GTGCAGTGGT	GCGACCACGG	CTCACGGCAG	100
87058	51	-----	-----	-----	-----	-----	100
87058.6	51	-----	-----	-----	-----	-----	100
87058.8	51	-----	-----	-----	-----	-----	100
87058.16	51	-----NCN	GGTGAGNAT	TCGGACNAGT	CCGAAAACGT	CCGGCAAGTC	100
		110	120	130	140	150	
caphepsin	101	CCTCAGCCAC	CCAGATGTAA	GCGATCTGGT	TCCCACCTCA	GCCTCCCGAG	150
87058	101	-----	-----	-----	-----	-----	150
87058.6	101	-----	-----	-----	-----	-----	150
87058.8	101	-----	-----	-----	-----	-----	150
87058.16	101	ACCCGCTCCG	CTGNCGCAG	GCTGGGNTGC	AGGCTCTCGG	NTGCAGNGCT	150
		160	170	180	190	200	
caphepsin	151	TAGTGGATCT	AGGATCCGGC	TTCCAACATG	TGGCAGtTCT	GGGCCTCCCT	200
87058	151	-----	-----	-----	-----	-----	200
87058.6	151	-----	-----	-----	-----	-----	200
87058.8	151	-----	-----	-----	-----	-----	200
87058.16	151	GGGTGGATCT	AGGATCCGGC	TTCCAACATG	TGGCAGtTCT	GGGCCTCCCT	200
		210	220	230	240	250	
caphepsin	201	CTGcTGCTTG	CTGGTGTGG	CCAATGCCCG	GAGcAGGcCC	TCTTTCATC	250
87058	201	-----	-----	-----	-----	-----	250
87058.6	201	-----	-----	-----	-----	-----	250
87058.8	201	-----	-----	-----	-----	-----	250
87058.16	201	CTGnTGCTTG	CTGGTGTGG	aCAATGCCCG	GAGgAGGnCC	TCTTTCATC	250
		260	270	280	290	300	
caphepsin	251	CCCTGTGGGA	TGAGCTGGTC	AaCTATGTCA	ACAAACGGAA	TACCACGTGG	300
87058	251	-----	-----	-----	-----	-----	300
87058.6	251	-----	-----	-----	-----	-----	300
87058.8	251	-----	-----	-----	-----	-----	300
87058.16	251	CCCTGTGGGA	TGAGCTGGTC	AnCTATGTCA	ACAAACGGAA	TACCACGTGG	300

FIGURE 8A

16/20

caphepsin	310	320	330	340	350	
87058	301	CAGGCCGGaA	ACAACTTCTA	CAACGTGGAC	ATGAGCTACT	TGAaGAGGcT
87058.6	301	-----	-----	-----	-----	350
87058.8	301	-----	-----	-----	-----	350
87058.16	301	nAGGCCGGgA	ACAACTTCTA	CAACGTGGAC	ATGAGCTACT	TGAnGAGGnT
caphepsin	360	370	380	390	400	
87058	351	ATGTGGTACC	TTCCCTGGGTG	GGCCCAAGCC	ACCCCAGAGA	GTTATGTTA
87058.6	351	-----	-----	-----	-----	400
87058.8	351	--GaGGTACC	TTCCCTGGGTG	GGCCCAAGCC	ACCCCAGAGA	GTTATGTTA
87058.16	351	ATGTGGTACC	TTCCCTGGGTG	GGCCCAAGCC	ACCCCAGAGA	GTTNTGTTA
caphepsin	410	420	430	440	450	
87058	401	CCGAGGACCT	GAAGCTGCCT	GCAAGCTTCG	ATGCACGGGA	ACAATGGCCA
87058.6	401	-----	-----	-----	-----	450
87058.8	401	CCGAGGACCT	GAAGCTGCCT	GCAAGCTTCG	ATGCACGGGA	ACAATGGCCA
87058.16	401	CCGAGGACCT	GANGCTGCCT	GCAAGCTTCG	AaGgACGGGA	ACAATGGCCA
caphepsin	460	470	480	490	500	
87058	451	CAGTGTCCA	CCATCAAAGA	GATCAGAGAC	CAGGGCTCCT	GTGGCTCCTG
87058.6	451	-----	-----	-----	-----	500
87058.8	451	CAGTGTCCA	CCATCAAAGA	GATCAGAGAC	CAGGGNTCCT	GTGGCTCCTG
87058.16	451	CAGTGTCCA	CCATCAAAGA	GATCAGAGAN	CAGGGCTCCT	GTGGNTCCTG
caphepsin	510	520	530	540	550	
87058	501	CTGGGCCCTTC	GGGGCTGTGG	AAGCCATCTC	TGACCGGATC	TGCATCCACA
87058.6	501	-----	-----	-----	-----	550
87058.8	501	CTGGGCCCTTC	GGGGCTGTGG	AAGCCATCTC	TGACCGGATC	TGNATCCACA
87058.16	501	CTGGGCCCTTC	GGGGCTGTGG	AAGNCATCTC	TGACCGGATC	TGCATCCACA
caphepsin	560	570	580	590	600	
87058	551	CCAATGCGCA	CGTCAGCGTG	GAGGTGTCGG	CGGAGGACCT	GCTCACATGC
87058.6	551	-----	-----	-----	-----	600
87058.8	551	CCAATGCGCA	CGTCAGCGTG	GAGGTGTCGG	CGGAGGAC-T	GCTCACATGC
87058.16	551	CCAATGNGCA	CGTCAGCGTG	GtGGTGTTCGG	NGGAGGACCT	GaTCACCTnT
caphepsin	610	620	630	640	650	
87058	601	TGTGGCAGCA	TGTGTGGGGA	CGGCTGTAAT	GGTGGCTATC	CTGCTGAAGC
87058.6	601	-----	-----	-----	-----	650
87058.8	601	TGTGGCAGNA	TGTGTGGGGA	CGGCTGTAAT	GGTGGCTATC	CTGCTGAAGC
87058.16	601	TGTGGtAGCA	TGTGTGGGGA	CGGCTGTAAT	GGTGGtTATC	CTGNTGAAGC

FIGURE 8B

17/20

caphepsin	660	670	680	690	700	
87058	651	-----	-----	-----	-----	700
87058.6	651	TTGGAACCTTC	TGGACAAGAA	AAGGCCTGGT	TTCTGGTGGC	CTCTATGAAT
87058.8	651	TTGGAACCTTC	TGGACAAGAA	AAGGCCTGGT	TTCTGGTGGC	CTCTATGAAT
87058.16	651	TTGGNACTTC	TGGACAAGAA	AAGGCCTGGT	TTCTGGTGGC	CTCTATGANT
	651	TNGGgNCTTC	TNagaAAGAA	AAGGCTNGT	TT--GGTGGC	CT-TATGACT
caphepsin	710	720	730	740	750	
87058	701	CCCATGTAGG	GTGCAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCACGTC
87058.6	701	-----	-----	-----	-----	750
87058.8	701	CCCATGTAGG	GTGCAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCACGTC
87058.16	701	CCCATGTAGG	GTGTAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCACGTC
	701	CCCATGT...	750
caphepsin	760	770	780	790	800	
87058	751	AACGGCTCCC	GGCCCCCATG	CACGGGGGAG	GGAGATAACCC	CCAAGTGTAG
87058.6	751	-----	-----	-----	-----	800
87058.8	751	AACGGCTCCC	GGCCCCCATG	CACGGGGGAG	GGAGATAACCC	CCAAGTGTAG
87058.16	751	AACGGtTCCC	GGgCCCCATG	CACGGNGGAG	GGAGATAACCC	CCAAGTGTAA
	751	800
caphepsin	810	820	830	840	850	
87058	801	CAAGATCTGT	GAGCCTGGCT	ACAGCCCCGAC	CTACAAACAG	GACAAGCACT
87058.6	801	-----	-----	-----	-----	850
87058.8	801	CAAGATCTGT	GAGCCTGGCT	ACAGCCCCGAC	CTACAAACAG	GACAAGCACT
87058.16	801	CAAGATCTGT	GAGCCTGGGT	ACAGtCCcga	CcACAAACAG	GAAAGCACT
	801	850
caphepsin	860	870	880	890	900	
87058	851	ACGGATACAA	TTCCTACAGC	GTCTCCAATA	GCGAGAAGGA	CATCATGGCC
87058.6	851	-----	-----	-----	-----	900
87058.8	851	ACGGATACAA	TTCCTACAGC	GTCTCCAATA	GCGAGAAGGA	CATCATGGCC
87058.16	851	ACGGATACAA	TTCT-CAGN	GTCTCCAATA	GtGAGAAGGA	CATCAT-GCC
	851	900
caphepsin	910	920	930	940	950	
87058	901	GAGATCTACA	AAAACGGCCC	CGTGGAGGGA	GCTTCTCTG	TGTATTGGA
87058.6	901	-----	-----	-----	-----	950
87058.8	901	GAGATCTACA	AAAACGGCCC	CGTGGAGGGA	GCTTCTCTG	TGTATTGGA
87058.16	901	GAGATCTACA	AtAACGGC..	950
	901	950
caphepsin	960	970	980	990	1000	
87058	951	CTTCCTGCTC	TACAAGTCAG	GAGTGTACCA	ACACGTCA	GGAGAGATGA
87058.6	951	-----	-----	-----	-----	1000
87058.8	951	CTTCCTGCTC	TACAAGTCAG	GAGTGTACCA	ACACGTCA	GGAGAGATGA
87058.16	951	1000
	951	1000

FIGURE 8C

		1010	1020	1030	1040	1050	
caphepsin	1001	TGGGTGGCCA	TGCCATCCGC	ATCCTGGCT	GGGGAGTGGA	GAATGGCACA	1050
87058	1001	-----	-----	-----	-----	-----	1050
87058.6	1001	TGGGTGGCCA	TGCCATCCGC	ATCCTGGCT	GGGGAGTGGA	GAATGGCACA	1050
87058.8	1001	-----	-----	-----	-----	-----	1050
87058.16	1001	-----	-----	-----	-----	-----	1050
		1060	1070	1080	1090	1100	
caphepsin	1051	cCCTACTGGC	TGGTTGCCA	CTCCTGGAAC	ACTGACTGGG	GTGACAATGG	1100
87058	1051	-----cGg	cagacGCCA	CTCCTGGAAC	ACTGACTGGG	GTGACAATGG	1100
87058.6	1051	aCCTACTGGC	TGGITGgCAA	CTCCTGGAAC	ACTGACTGGG	GTGACAATGG	1100
87058.8	1051	-----	-----	-----	-----	-----	1100
87058.16	1051	-----	-----	-----	-----	-----	1100
		1110	1120	1130	1140	1150	
caphepsin	1101	CTTCTTTAAA	ATACTCAGAG	GACAGGATCA	CTGTGGAATC	GAATCAGAAG	1150
87058	1101	CTTCTTTAAA	ATACTCAGAG	GACAGGTTCA	CTGTGGAATC	GAATCAGAAG	1150
87058.6	1101	GTTC-----	-----	-----	-----	-----	1150
87058.8	1101	-----	-----	-----	-----	-----	1150
87058.16	1101	-----	-----	-----	-----	-----	1150
		1160	1170	1180	1190	1200	
caphepsin	1151	TGGTGGCTGG	AATTCCACGC	ACCGATCAGT	ACTGGGAAAA	GATCTAAATCT	1200
87058	1151	TGGTGGCTGG	AATTCCACGC	ACCGTTCA	ACTGGGAAAA	GNTCTAAATCT	1200
87058.6	1151	-----	-----	-----	-----	-----	1200
87058.8	1151	-----	-----	-----	-----	-----	1200
87058.16	1151	-----	-----	-----	-----	-----	1200
		1210	1220	1230	1240	1250	
caphepsin	1201	GCCGTGGGCC	TGTCGTGCCA	GTCCTGGGGG	CGAGATCGGG	GTAGAAATGC	1250
87058	1201	GCCGTGGGCC	TNTCGTGCCA	GTCCTGGGGG	CGAGATGGGG	GTAGAAATGC	1250
87058.6	1201	-----	-----	-----	-----	-----	1250
87058.8	1201	-----	-----	-----	-----	-----	1250
87058.16	1201	-----	-----	-----	-----	-----	1250
		1260	1270	1280	1290	1300	
caphepsin	1251	ATTTTATCT	TTAAGTTCAC	GTAAGATACA	AGTTTCAGgC	AGGGTCTgAA	1300
87058	1251	ATTTTATCT	TTAAGTTCAC	GTAAGATACA	AGTTTCAGaC	AGGGTCTnAA	1300
87058.6	1251	-----	-----	-----	-----	-----	1300
87058.8	1251	-----	-----	-----	-----	-----	1300
87058.16	1251	-----	-----	-----	-----	-----	1300
		1310	1320	1330	1340	1350	
caphepsin	1301	GGaCTGGaTT	gGCCAAACAT	CAGACCTGTC	TTCCAAGGAG	ACCAAGTCCT	1350
87058	1301	GGcCTGGnTT	nGCCAAAnAT	CAGACCTGT	-----	-----	1350
87058.6	1301	-----	-----	-----	-----	-----	1350
87058.8	1301	-----	-----	-----	-----	-----	1350
87058.16	1301	-----	-----	-----	-----	-----	1350

FIGURE 8D

	1360	1370	1380	1390	1400	
caphepsin	1351 GGCTACATCC	CAGCCTGTGG	TTACAGTGCA	GACAGGCCAT	GTGAGGCCACC	1400
87058	1351	1400
87058.6	1351	1400
87058.8	1351	1400
87058.16	1351	1400
	1410	1420	1430	1440	1450	
caphepsin	1401 GCTGCCAGCA	CAGAGCGTCC	TTCCCCCTGT	AGACTAGTGC	CGTGGGAGTA	1450
87058	1401	1450
87058.6	1401	1450
87058.8	1401	1450
87058.16	1401	1450
	1460	1470	1480	1490	1500	
caphepsin	1451 CCTGCTGCC	AGCTGCTGTG	GCCCCCTCCG	TGATCCATCC	ATCTCCAGGG	1500
87058	1451	1500
87058.6	1451	1500
87058.8	1451	1500
87058.16	1451	1500
	1510	1520	1530	1540	1550	
caphepsin	1501 AGCAAGACAG	AGACCGAGGA	TGGAAAGCGG	AGTTCTAAC	AGGATGAAAG	1550
87058	1501	1550
87058.6	1501	1550
87058.8	1501	1550
87058.16	1501	1550
	1560	1570	1580	1590	1600	
caphepsin	1551 TTCCCCCATC	AGTTCCCCCA	GTACCTCCAA	GCAAGTAGCT	TTCCACATTT	1600
87058	1551	1600
87058.6	1551	1600
87058.8	1551	1600
87058.16	1551	1600
	1610	1620	1630	1640	1650	
caphepsin	1601 GTCACAGAAA	TCAGAGGAGA	GATGGTGTG	GGAGCCCTTT	GGAGAACGCC	1650
87058	1601	1650
87058.6	1601	1650
87058.8	1601	1650
87058.16	1601	1650

FIGURE 8E

20/20

		1660	1670	1680	1690	1700	
capthepsin	1651	AGTCTCCAGG	TCCCCCTGCA	TCTATCGAGT	TTGCAATGTC	ACAACCTCTC	1700
87058	1651	1700
87058.6	1651	1700
87058.8	1651	1700
87058.16	1651	1700
		1710	1720	1730	1740	1750	
capthepsin	1701	TGATCTTGTG	CTCAGCATGA	TTCTTTAATA	GAAGTTTAT	TTTCGTGCA	1750
87058	1701	1750
87058.6	1701	1750
87058.8	1701	1750
87058.16	1701	1750
		1760	1770	1780	1790	1800	
capthepsin	1751	CTCTGCTAAT	CATGTGGGTG	AGCCAGTGGGA	ACAGCGGGAG	CCTGTGCTGG	1800
87058	1751	1800
87058.6	1751	1800
87058.8	1751	1800
87058.16	1751	1800
		1810	1820	1830	1840	1850	
capthepsin	1801	TTTGCAGATT	GCCTCCTAAT	GACGGGGCTC	AAAAGGAAC	CAAGTGGTCA	1850
87058	1801	1850
87058.6	1801	1850
87058.8	1801	1850
87058.16	1801	1850
		1860	1870	1880	1890	1900	
capthepsin	1851	GGAGTTGTTT	CTGACCCACT	GATCTCTACT	ACCACAAGGA	AAATAGTTTA	1900
87058	1851	1900
87058.6	1851	1900
87058.8	1851	1900
87058.16	1851	1900
		1910	1920	1930	1940	1950	
capthepsin	1901	GGAGAAACCA	GCTTTTACTG	TTTTGAAAAA	ATTACAGCTT	CACCCCTGTCA	1950
87058	1901	1950
87058.6	1901	1950
87058.8	1901	1950
87058.16	1901	1950
		1960	1970	1980	1990	2000	
capthepsin	1951	AGTTAACAAAG	GAATGCCTGT	GCCAATAAAA	GGTTCTCCA	ACITGA...	2000
87058	1951	2000
87058.6	1951	2000
87058.8	1951	2000
87058.16	1951	2000

FIGURE 8F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/08501

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68 C12P19/34 C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS. EDITOR INNIS M.; PUBLISHER ACADEMIC, 1990, SAN DIEGO, CALIF., pages 219-27, XP002015609 OCHMAN, H. ET AL: "Amplification of flanking sequences by inverse PCR" see whole article ---	1-8
X	BIOTECHNIQUES, vol. 18, no. 5, May 1995, pages 762-64, XP000509322 COOLIDGE C ET AL: "Run-around PCR: A novel way to create duplications using polymerase chain reaction" see the whole document ---	1-8 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

1 Date of the actual completion of the international search

10 October 1996

Date of mailing of the international search report

25.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

International Application No
PL /US 96/08501

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 268, no. 12, 1993, pages 8842-50, XP000604943 LEE, D. ET AL.: "Molecular cloning and genomic organization of a gene for luciferin-binding protein from dinoflagellate Gonyaulax polyedra" see the whole document ---	1-8
X	US,A,4 994 370 (SILVER) 19 February 1991 see the whole document ---	1-8
X	JOURNAL OF VIROLOGICAL METHODS, vol. 49, no. 3, January 1994, pages 269-84, XP000606337 TSUEI D-J ET AL: "Inverse polymerase chain reaction for cloning cellular sequences adjacent to integrated hepatitis b virus in hepatocellular carcinomas" see the whole document ---	1-8
X	WO,A,90 14423 (THE INFERGENE CO.) 29 November 1990 see page 19 ---	1-8
A	WO,A,93 12257 (HYBRITECH INC) 24 June 1993 see the whole document ---	1-8
A	NUCLEIC ACIDS RESEARCH, vol. 19, 1991, pages 3055-60, XP002015610 PARKER J. ET AL: "Walking PCR" cited in the application -----	


INTERNATIONAL SEARCH REPORT


Information on patent family members

International Application No


PCT/US 96/08501

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-4994370	19-02-91	NONE		
WO-A-9014423	29-11-90	NONE		
WO-A-9312257	24-06-93	AU-A- 3274793 US-A- 5512463		19-07-93 30-04-96




**FIGURE 1**


2/20

**FIGURE 2**


3/20

**FIGURE 3**

4/20

**FIGURE 4**

5/20

**FIGURE 5**

6/20




FIGURE 6

7/20

	10	20	30	40	50	
Hsp 90	1 CTCGGGGCA	GTGTTGGGAC	TGTCTGGTA	TGGGAAGCA	AGGCTACGT	50
14201	1 -----	-----	-----	-----	-----	50
14201.3	1 -----	-----	-----	-----	-----	50
14201.5	1 -----	-----	-----	-----	-----	50
14201.13	1 -----	-----	-----	-----	-----	50
	60	70	80	90	100	
Hsp 90	51 GCTCACTATT	ACGTATAATC	CTTTTCCTT	CAGATGCCT	GAGGAAGTGC	100
14201	51 -----	-----	-----	-----	-----	100
14201.3	51 GCTCACTATT	ACGTATAATC	CTTTTCCTTN	CAGATGCCT	GAGGAAGTGC	100
14201.5	51 GCTCACTATT	ACGTATAATC	CTTTTCCTTT	CAGATGCCT	GAGGAAGTGC	100
14201.13	51 -----	-----	-----	-----	-----	100
	110	120	130	140	150	
Hsp 90	101 ACCATGGAGA	GGAGGAGGTG	GAGACTTTC	CCTTCAGGC	AGAAATTGCC	150
14201	101 -----	-----	-----	-----	-----	150
14201.3	101 ACCATGGAGA	GGAGGAGGTG	GAGACTTTC	CCTTCAGGC	AGAAATTGCC	150
14201.5	101 ACCATGGAGA	GGAGGAGGTG	GAGACTTTC	CCTTCAGGC	AGAAATTGCC	150
14201.13	101 -----	-----	-----	-----	-----	150
	160	170	180	190	200	
Hsp 90	151 CACTCTATGT	CCCTCATCAT	CAATACCTTC	TATTCAAACA	AGGAGATTT	200
14201	151 -----	-----	-----	-----	-----	200
14201.3	151 CACTCTATGT	CCCTCATCAT	CAATACCTCC	TATTCAAACA	AGGAGATTT	200
14201.5	151 CACTCTATGT	CCCTCATCAT	CAATACCTCC	TATTCAAACA	AGGAGATTT	200
14201.13	151 -----	-----	-----	-----	-----	200
	210	220	230	240	250	
Hsp 90	201 CCTTOGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCGCTGGAC	AAGATTCGCT	250
14201	201 -----	-----	-----	-----	-----	250
14201.3	201 CCTTOGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCGCTGGAC	AAGATTCGCT	250
14201.5	201 CCTTOGGGAG	TTGATCTCTA	ATGCTTCTGA	TGCGCTGGAC	AAGATTCGCT	250
14201.13	201 -----	-----	-----	-----	-----	250
	260	270	280	290	300	
Hsp 90	251 ATGAGAGCCT	GACAGACCT	TGAGAGTGG	ACAGTGGTAA	AGAGCTGAAA	300
14201	251 -----	-----	-----	-----	-----	300
14201.3	251 ATGAGAGCCT	GACAGACCT	TGAGAGTGG	ACAGTGGTAA	AGAGCTGAAA	300
14201.5	251 ATGAGAGCCT	GACAGACCT	TGAGAGTGG	ACAGTGGTAA	AGAGCTGAAA	300
14201.13	251 -----	-----	-----	-----	-----	300

FIGURE 7A

8/20

	310	320	330	340	350	
Hsp 90	301 ATTGACATCA TCCCCAACCC TCAGGAAACTG ACCCTGACTT TGGTAGACAC					350
14201	301 -----					350
14201.3	301 ATTGACATCA TCCCCAACCC TCAGGAAACTG ACCCTGACTT TGGTAGACAC					350
14201.5	301 ATTGACATCA TCCCCAACCC TCAGGAAACTG ACCCTGACTT TGGTAGACAC					350
14201.13	301 -----					350
	360	370	380	390	400	
Hsp 90	351 AGGCATGGC ATGACCAAAG CTGATCTCAT AAATAATTG GGAACCATG					400
14201	351 -----					400
14201.3	351 AGGCATGGC ATGACCAAAG CTGATCTCAT NACTTATTCG GGGAGCCAT					400
14201.5	351 AGGCATGGC ATGACCAAAG CTGATCTCAT AAATAATTG GGAACCATG					400
14201.13	351 -----					400
	410	420	430	440	450	
Hsp 90	401 CCAAGTCTGG TACTAAAGCA TTCAATGGAGG CTCTTCAGGC TGGTGCAGAC					450
14201	401 -----					450
14201.3	401 CCAAGTCTGG TACTAAAGCA TTCAATGGAGG CTCTTCAGGC TGGTGCAGAC					450
14201.5	401 CCAAGTCTGG TACTAAAGCA TTCAATGGAGG CTCTTCAGGC TGGTGCAGAC					450
14201.13	401 -----					450
	460	470	480	490	500	
Hsp 90	451 ATCTCCATGA TTGGGCAGT TGGTGTGGC TttTATTCTG CCTACTTGGT					500
14201	451 -----					500
14201.3	451 ATCTCCATGA TTGGGCAGT GGGTGTGGC TttTATTCTG CCTACTTGGT					500
14201.5	451 ATCTCCATGA TTGGGCAGT GGGTGTGGC TttTATTCTG CCTACTTGGT					500
14201.13	451 -----					500
	510	520	530	540	550	
Hsp 90	501 GGCAGAGAAA GTGGTTGTGA TCAAGAAAGCA CAAAGATGAT GAGAGTATG					550
14201	501 -----					550
14201.3	501 GGCAGAGAAA NNT					550
14201.5	501 GGCAGAGAAA GTGGTTGTGA TCA					550
14201.13	501 -----				TT GAGAGTATG	550
	560	570	580	590	600	
Hsp 90	551 CTTGGGAGTC TtCTGCTGGA GGTTCCTCA CTtGCGTGC TGACCATGGT					600
14201	551 -----					600
14201.3	551 -----					600
14201.5	551 -----					600
14201.13	551 -TcaGAGT- TACTCTGGA GGTTCCTCA CTtGCGTGC TGACCATGGT					600
	610	620	630	640	650	
Hsp 90	601 GAGGCCATTG GcatGGTAC CAAAGTGATC CTCCATCTCA AAGAAGATCA					650
14201	601 -----					650
14201.3	601 -----					650
14201.5	601 -----					650
14201.13	601 GAGGCCATTG GcatGGTAC CAAAGTGATC CTCCATCTCA AAGAAGATCA					650

FIGURE 7B

9/20

	660	670	680	690	700	
Hsp 90	651 GACAGAGTAC	CTAGAaGAGA	GGCGGgTCAA	AGaAGTAGTC	AeGAGGCATT	700
14201	651	-----	-----	-----	-----	700
14201.3	651	-----	-----	-----	-----	700
14201.5	651	-----	-----	-----	-----	700
14201.13	651 GACAGAGTAC	CTAGAaGAGA	GGCGGgTCAA	AGaAGTAGTC	AeGAGGCATT	700
	710	720	730	740	750	
Hsp 90	701 CTCAGTCAT	AGGCTATCCC	ATCACCCTTT	ATTTGGAGAA	GGaACGGAGAC	750
14201	701	-----	-----	-----	-----	750
14201.3	701	-----	-----	-----	-----	750
14201.5	701	-----	-----	-----	-----	750
14201.13	701 CTCAGTCAT	AGGCTATCCC	ATCACCCTTT	ATTTGGAGAA	GGaACGGAGAC	750
	760	770	780	790	800	
Hsp 90	751 AAGGAaTTTA	GtGATGATGA	GGCAaGGAA	GAGAAaGGTC	AGAAABGAAGA	800
14201	751	-----	-----	-----	-----	800
14201.3	751	-----	-----	-----	-----	800
14201.5	751	-----	-----	-----	-----	800
14201.13	751 AAGGAaTTTA	GnGATGATGA	GGCAaGGAA	GAGAAaGGTC	AGAAABGAAGA	800
	810	820	830	840	850	
Hsp 90	801 GGAAgGTAAC	GATGATGAAG	AAAaGCCCBA	GATCGAaGAT	GTGGgTTCAAG	850
14201	801	-----	-----	-----	-----	850
14201.3	801	-----	-----	-----	-----	850
14201.5	801	-----	-----	-----	-----	850
14201.13	801 GGAAgGTAAC	GATGATGAAG	AAAaGCCCBA	GATCGAaGAT	GTGGgTTCAAG	850
	860	870	880	890	900	
Hsp 90	851 ATGAGGAGGA	TGACAGCGGT	aaGATGAA	AGAAAGAAaAC	TaaGAaGATC	900
14201	851	-----	-----	-----	-----	900
14201.3	851	-----	-----	-----	-----	900
14201.5	851	-----	-----	-----	-----	900
14201.13	851 ATGAGGAGGA	TGACAGCGGT	aaGATGAA	AGAAAGAAaAC	TaaGAaGATC	900
	910	920	930	940	950	
Hsp 90	901 AAACAGAAAT	ACATTGATCA	CGAAAGAACTA	AACAAAGACCA	AGCCTATTTG	950
14201	901	-----	-----	-----	-----	950
14201.3	901	-----	-----	-----	-----	950
14201.5	901	-----	-----	-----	-----	950
14201.13	901	-----	-----	-----	-----	950
	960	970	980	990	1000	
Hsp 90	951 GACGAGAAAC	OCTGATGACA	TCACCCGAGA	GGAGTATGGA	CAATTCTACA	1000
14201	951	-----	-----	-----	-----	1000
14201.3	951	-----	-----	-----	-----	1000
14201.5	951	-----	-----	-----	-----	1000
14201.13	951	-----	-----	-----	-----	1000

FIGURE 7C

10/20

Hsp 90	1010	1020	1030	1040	1050	
14201	1001	TAATGACTGG	GAAGACCACT	TGGCAGTCAC	GCACCTTTCT	1050
14201.3	1001	1050
14201.5	1001	1050
14201.13	1001	1050
	1060	1070	1080	1090	1100	
Hsp 90	1051	GTAGAAAGTC	ACTTGGATT	CAGGCGATTG	CTATTTATTC	CTCGTCGGC
14201	1051	1100
14201.3	1051	1100
14201.5	1051	1100
14201.13	1051	1100
	1110	1120	1130	1140	1150	
Hsp 90	1101	TCCCTTTGAC	CTTTTTGAGA	ACAAGAAGAA	AAAGAAACAC	ATCAGACTCT
14201	1101	1150
14201.3	1101	1150
14201.5	1101	1150
14201.13	1101	1150
	1160	1170	1180	1190	1200	
Hsp 90	1151	ATGTCGGCG	TGTTCATC	ATGGAGCT	GTAATGAGT	GATACCAGAG
14201	1151	ATGTCGGCG	TGTTCATC	ATGGAGCT	GTAATGAGT	GATACCAGAG
14201.3	1151	1200
14201.5	1151	1200
14201.13	1151	1200
	1210	1220	1230	1240	1250	
Hsp 90	1201	TATCTCAATT	TTATCCGTGG	TGTGGTTGAC	TCTGAGGATC	TGCCCTCTGAA
14201	1201	TATCTCAATT	TTATCCGTGG	TGTGGTTGAC	TCTGAGGATC	TGCCCTCTGAA
14201.3	1201	1250
14201.5	1201	1250
14201.13	1201	1250
	1260	1270	1280	1290	1300	
Hsp 90	1251	CATCTCCCGA	GAATGCTCC	ACCGAGGCAA	AACTTCAAA	GCATTCGCA
14201	1251	CATCTCCCGA	GAATGCTCC	ACCGAGGCAA	AACTTCAAA	GCATTCGCA
14201.3	1251	1300
14201.5	1251	1300
14201.13	1251	1300
	1310	1320	1330	1340	1350	
Hsp 90	1301	AAACACATTGT	TAAGAGTGC	CTTnAGCTCT	TCTCTnAGCT	GGCGAGAGAC
14201	1301	AAACACATTGT	TAAGAGTGC	CTTnAGCTCT	TCTCTnAGCT	GGCGAGAGAC
14201.3	1301	1350
14201.5	1301	1350
14201.13	1301	1350

FIGURE 7D

11/20

	1360	1370	1380	1390	1400	
Hsp 90	1351 AAGGAGAATT	ACAGAGAATT	CTATGAGGCA	TTCTCTAAAA	ATCTCAGCT	1400
14201	1351 AAGG-GGATT	TCAGAGAATT	CTTGGGGG	-----	-----	1400
14201.3	1351	1400
14201.5	1351	1400
14201.13	1351	1400
	1410	1420	1430	1440	1450	
Hsp 90	1401 TGGAATCCAC	GAAGACTCCA	CTTACCGGGG	CCGCGCTGCT	GAGCTGTTGC	1450
14201	1401 -----	-----	-----	-----	-----	1450
14201.3	1401	1450
14201.5	1401	1450
14201.13	1401	1450
	1460	1470	1480	1490	1500	
Hsp 90	1451 GCTATCATAC	CTCCCACTCT	GGAGATGAGA	TGACATCTCT	GTCAGAGTAT	1500
14201	1451 -----	-----	-----	-----	-----	1500
14201.3	1451	1500
14201.5	1451	1500
14201.13	1451	1500
	1510	1520	1530	1540	1550	
Hsp 90	1501 GTTTCTCCCA	TGAAGGAGAC	AACGAAGTCC	ATCTATTACA	TCACTGGTGA	1550
14201	1501 -----	-----	-----	-----	-----	1550
14201.3	1501	1550
14201.5	1501	1550
14201.13	1501	1550
	1560	1570	1580	1590	1600	
Hsp 90	1551 GAGCAGAGAG	CAGGTGGGCA	ACTCAGCTT	TGTGGAGGGA	GTGGGGAAAC	1600
14201	1551 -----	-----	-----	-----	-----	1600
14201.3	1551	1600
14201.5	1551	1600
14201.13	1551	1600
	1610	1620	1630	1640	1650	
Hsp 90	1601 GGGGCTTCTGA	GGTGTCTATAT	ATGACCGAGC	CCATGACGA	GTACTGTGTC	1650
14201	1601 -----	-----	-----	-----	-----	1650
14201.3	1601	1650
14201.5	1601	1650
14201.13	1601	1650

FIGURE 7E

12/20

	1660	1670	1680	1690	1700	
Hsp 90	1651 CAGCAGCTCA	AGGAATTTGA	TGCGAAGAGG	CTGGTCTCAG	TTACCAAGGA	1700
14201	1651	-----	-----	-----	-----	1700
14201.3	1651	-----	-----	-----	-----	1700
14201.5	1651	-----	-----	-----	-----	1700
14201.13	1651	-----	-----	-----	-----	1700
	1710	1720	1730	1740	1750	
Hsp 90	1701 CGGTCTGAGG	CTGCCCTGAGG	ATGAGGGAGG	GAAGAGAGAG	ATGGAGAGGA	1750
14201	1701	-----	-----	-----	-----	1750
14201.3	1701	-----	-----	-----	-----	1750
14201.5	1701	-----	-----	-----	-----	1750
14201.13	1701	-----	-----	-----	-----	1750
	1760	1770	1780	1790	1800	
Hsp 90	1751 GCPAGGCRAA	GTITGAGAAC	CTCTCGAAGC	TCATGAAAGA	AATCTTAGAT	1800
14201	1751	-----	-----	-----	-----	1800
14201.3	1751	-----	-----	-----	-----	1800
14201.5	1751	-----	-----	-----	-----	1800
14201.13	1751	-----	-----	-----	-----	1800
	1810	1820	1830	1840	1850	
Hsp 90	1801 AAGMAGGTG	AGAAAGGTGAC	AACTCTCCAT	AGAATTCGT	CTTCACCTTG	1850
14201	1801	-----	-----	-----	-----	1850
14201.3	1801	-----	-----	-----	-----	1850
14201.5	1801	-----	-----	-----	-----	1850
14201.13	1801	-----	-----	-----	-----	1850
	1860	1870	1880	1890	1900	
Hsp 90	1851 CTGCATTGIG	ACCAAGCCT	ACGGCTGAGAC	AGCCCATATG	GAGCGGATCA	1900
14201	1851	-----	-----	-----	-----	1900
14201.3	1851	-----	-----	-----	-----	1900
14201.5	1851	-----	-----	-----	-----	1900
14201.13	1851	-----	-----	-----	-----	1900
	1910	1920	1930	1940	1950	
Hsp 90	1901 TGAAACCCA	GGCCTTGGG	GACAACCTA	CCATGGCTA	TAATGATGGGC	1950
14201	1901	-----	-----	-----	-----	1950
14201.3	1901	-----	-----	-----	-----	1950
14201.5	1901	-----	-----	-----	-----	1950
14201.13	1901	-----	-----	-----	-----	1950
	1960	1970	1980	1990	2000	
Hsp 90	1951 AAAAAGCACC	TGGAGATCAA	CCCTGACCAAC	CCCATGGGG	AGACGGCTGCG	2000
14201	1951	-----	-----	-----	-----	2000
14201.3	1951	-----	-----	-----	-----	2000
14201.5	1951	-----	-----	-----	-----	2000
14201.13	1951	-----	-----	-----	-----	2000

FIGURE 7F

13/20

		2010	2020	2030	2040	2050	
Hsp 90	2001	GGAGAAGCT	GAGGCCGACA	AGAATGATAA	GGCAGTTAAC	GAACCTGGTGG	2050
14201	2001	2050
14201.3	2001	2050
14201.5	2001	2050
14201.13	2001	2050
		2060	2070	2080	2090	2100	
Hsp 90	2051	TGCTGCTGTT	TGAAACCGCC	CTGCTATCTT	CTGGCTTTC	CCTTGAGGAT	2100
14201	2051	2100
14201.3	2051	2100
14201.5	2051	2100
14201.13	2051	2100
		2110	2120	2130	2140	2150	
Hsp 90	2101	CCCCAGACCC	ACTCCACCCG	CTATCTATCC	ATGATCAAGC	TAGGTCTAGG	2150
14201	2101	2150
14201.3	2101	2150
14201.5	2101	2150
14201.13	2101	2150
		2160	2170	2180	2190	2200	
Hsp 90	2151	TATTGATGAA	GATGAAGTGG	CAGCAGAGGA	ACCCATATCT	GCAGTTGCTG	2200
14201	2151	2200
14201.3	2151	2200
14201.5	2151	2200
14201.13	2151	2200
		2210	2220	2230	2240	2250	
Hsp 90	2201	ATGAGATCCC	CCCTCTCGAG	GGCGATGAGG	ATGCGTCCTG	CATGGAAAGA	2250
14201	2201	2250
14201.3	2201	2250
14201.5	2201	2250
14201.13	2201	2250
		2260	2270	2280	2290	2300	
Hsp 90	2251	GTCGATTAGG	TTAGGAGTTG	ATAGTTGGAA	AACTTGTGCC	CTTGTATACT	2300
14201	2251	2300
14201.3	2251	2300
14201.5	2251	2300
14201.13	2251	2300
		2310	2320	2330	2340	2350	
Hsp 90	2301	GTCCCCATGG	GCTCCCACTG	CAGCCTCGAG	TGCCCGTGTG	CCACCGTGGCT	2350
14201	2301	2350
14201.3	2301	2350
14201.5	2301	2350
14201.13	2301	2350

FIGURE 7G

14/20

	2360	2370	2380	2390	2400	
Hsp 90	2351	CCCCCTGCTG	CCTGCTCTAGC	TTTTTTTCCC	TCTCTCTGCC	TTGCTGTTGAA
14201	2351	2400
14201.3	2351	2400
14201.5	2351	2400
14201.13	2351	2400
	2410	2420	2430	2440	2450	
Hsp 90	2401	GGCAGTAAAC	TAAGGGTGTC	AAGCCCCATT	CCCTCTCTAC	TCTTGACAGC
14201	2401	2450
14201.3	2401	2450
14201.5	2401	2450
14201.13	2401	2450
	2460	2470	2480	2490	2500	
Hsp 90	2451	AGGATTGGAT	CTTCTGTATT	CTGGCTTATT	TTATTTCTT	CATTTTGTC
14201	2451	2500
14201.3	2451	2500
14201.5	2451	2500
14201.13	2451	2500
	2510	2520	2530	2540	2550	
Hsp 90	2501	TGAAATTAAC	CTATGCAAAA	TAAGGATAT	CCCTTTTTA	TAC.....
14201	2501	2550
14201.3	2501	2550
14201.5	2501	2550
14201.13	2501	2550

FIGURE 7H

15/20

	10	20	30	40	50	
cathepsin	1 TCGGGCAGG	CCGACCGTC	CCCTGGGGG	AGGATGGCT	GCGGGCTTC	50
87058	1	-----	-----	-----	-----	50
87058.6	1	-----	-----	-----	-----	50
87058.8	1	-----	-----	-----	-----	50
87058.16	1	-----	-----	-----	-----	50
	60	70	80	90	100	
cathepsin	51 GGCTGGAGCG	CTGGGCTGGT	GTGCGATGTT	GCGGACCGAGG	CTAACGGGAG	100
87058	51 -----	-----	-----	-----	-----	100
87058.6	51 -----	-----	-----	-----	-----	100
87058.8	51 -----	-----	-----	-----	-----	100
87058.16	51 -----NCN	GGTGTGAGNAT	TGGGACAGT	CCGAAACGT	CGGGCAAGTC	100
	110	120	130	140	150	
cathepsin	101 CCTCAAGCCAC	CCAGATGTAA	GCGATCTGGT	TCCACCTCA	GGCTGGGAG	150
87058	101 -----	-----	-----	-----	-----	150
87058.6	101 -----	-----	-----	-----	-----	150
87058.8	101 -----	-----	-----	-----	-----	150
87058.16	101 ACCCGCTTCG	CTGNGGCGAG	GCTGGGNAGC	AGGCTCTCGG	NTGCAAGNCT	150
	160	170	180	190	200	
cathepsin	151 TAGTGGAACT	AGGATCGGAC	TTCGAAACATG	TGGCGAGCTCT	GGGGCTCCCT	200
87058	151 -----	-----	-----	-----	-----	200
87058.6	151 -----	-----	-----	-----	-----	200
87058.8	151 -----	-----	-----	-----	-----	200
87058.16	151 GGGTGGATCT	AGGATCCCGC	TTCGAAACATG	TGGCGAGCTCT	GGGGCTCCCT	200
	210	220	230	240	250	
cathepsin	201 CTGAGTGCTG	CTGGTGTGG	CCAAATGCCCG	GAACGAGGAC	TCTTTCCATC	250
87058	201 -----	-----	-----	-----	-----	250
87058.6	201 -----	-----	-----	-----	-----	250
87058.8	201 -----	-----	-----	-----	-----	250
87058.16	201 CTGAGTGCTG	CTGGTGTGG	CCAAATGCCCG	GAACGAGGAC	TCTTTCCATC	250
	260	270	280	290	300	
cathepsin	251 CCCTGTCGGA	TGAGCTGGTC	ATCTATGTC	ACAAACGGAA	TACCAAGTGG	300
87058	251 -----	-----	-----	-----	-----	300
87058.6	251 -----	-----	-----	-----	-----	300
87058.8	251 -----	-----	-----	-----	-----	300
87058.16	251 CCCTGTCGGA	TGAGCTGGTC	ATCTATGTC	ACAAACGGAA	TACCAAGTGG	300

FIGURE 8A

16/20

caphepsin	310	320	330	340	350	
87058	301	-----	CAACGTGGAC	ATGAGCTACT	TGAGGAGGCT	350
87058.6	301	-----	-----	-----	-----	350
87058.8	301	-----	-----	-----	-----	350
87058.16	301	-----	CAACGTGGAC	ATGAGCTACT	TGAGGAGGCT	350
caphepsin	360	370	380	390	400	
87058	351	ATGTGGTACC	TTCTCTGGTG	GGCCCAAGCC	ACCCAGAGA	GTTATGTTA
87058.6	351	-----	-----	-----	-----	400
87058.8	351	-----	-----	-----	-----	400
87058.16	351	-----	GGCTTACC	TTCTCTGGTG	GGCCCAAGCC	ACCCAGAGA
caphepsin	410	420	430	440	450	
87058	401	CCGAGGACCT	GAAGCTGCCT	GCAAGCTTCG	ATGCACGGGA	ACAAATGGCCA
87058.6	401	-----	-----	-----	-----	450
87058.8	401	-----	-----	-----	-----	450
87058.16	401	CCGAGGACCT	GAAGCTGCCT	GCAAGCTTCG	ATGCACGGGA	ACAAATGGCCA
caphepsin	460	470	480	490	500	
87058	451	CAGTGTCCCA	CCATCAAAAGA	GATCAGAGAC	CAGGGCTCCT	GTGGCTCTTG
87058.6	451	-----	-----	-----	-----	500
87058.8	451	CAGTGTCCCA	CCATCAAAAGA	GATCAGAGAC	CAGGGCTCCT	GTGGCTCTTG
87058.16	451	CAGTGTCCCA	CCATCAAAAGA	GATCAGAGAC	CAGGGCTCCT	GTGGCTCTTG
caphepsin	510	520	530	540	550	
87058	501	CTGGGCCCTTC	GGGGCTGTGG	AAAGCCATCTC	TGACCGGATC	TGCATCCACA
87058.6	501	-----	-----	-----	-----	550
87058.8	501	CTGGGCCCTTC	GGGGCTGTGG	AAAGCCATCTC	TGACCGGATC	TGCATCCACA
87058.16	501	CTGGGCCCTTC	GGGGCTGTGG	AAAGCCATCTC	TGACCGGATC	TGCATCCACA
caphepsin	560	570	580	590	600	
87058	551	CCAAATGGCA	CGTCAGGCTG	GGGGTGTGG	CGGAGGACCT	GCTCACATGC
87058.6	551	-----	-----	-----	-----	600
87058.8	551	CCAAATGGCA	CGTCAGGCTG	GGGGTGTGG	CGGAGGACCT	GCTCACATGC
87058.16	551	CCAAATGGCA	CGTCAGGCTG	GGGGTGTGG	CGGAGGACCT	GCTCACATGC
caphepsin	610	620	630	640	650	
87058	601	TGTGGCAAGCA	TGTGTGGGCA	CGGCTGTAAAT	GGTGGCTATC	CTGCTGAACC
87058.6	601	-----	-----	-----	-----	650
87058.8	601	-----	-----	-----	-----	650
87058.16	601	TGTGGCAAGCA	TGTGTGGGCA	CGGCTGTAAAT	GGTGGCTATC	CTGCTGAACC
					-----	650
					GTGAGG	650
					-----	650
					GTGAGG	650
					-----	650

FIGURE 8B

17/20

	660	670	680	690	700	
caphepsin	651 TTGGAACTTC	TGGACAAGAA	AAAGCCCTGGT	TTCTGGTGGC	CTCTATGAA	700
87058	651	-----	-----	-----	-----	700
87058.6	651 TTGGAACTTC	TGGACAAGAA	AAAGCCCTGGT	TTCTGGTGGC	CTCTATGAA	700
87058.8	651 TTGGAACTTC	TGGACAAGAA	AAAGCCCTGGT	TTCTGGTGGC	CTCTATGAA	700
87058.16	651 TTGGAACTTC	TGGACAAGAA	AAAGCCCTGGT	TTCTGGTGGC	CTCTATGAA	700
	710	720	730	740	750	
caphepsin	701 CCCATGTAGG	GTCAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCAAGTC	750
87058	701	-----	-----	-----	-----	750
87058.6	701 CCCATGTAGG	GTCAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCAAGTC	750
87058.8	701 CCCATGTAGG	GTCAGACCG	TACTCCATCC	CTCCCTGTGA	GCACCAAGTC	750
87058.16	701 CCCATGTAGG	...	-----	-----	-----	750
	760	770	780	790	800	
caphepsin	751 AACGGCTCCC	GGCCCCATG	CAGGGGGGAG	GGAGATACCC	CCAAAGTGTAG	800
87058	751	-----	-----	-----	-----	800
87058.6	751 AACGGCTCCC	GGCCCCATG	CAGGGGGGAG	GGAGATACCC	CCAAAGTGTAG	800
87058.8	751 AACGGCTCCC	GGCCCCATG	CAGGGGGGAG	GGAGATACCC	CCAAAGTGTAG	800
87058.16	751	-----	-----	-----	-----	800
	810	820	830	840	850	
caphepsin	801 CAAGATCTGT	GACCTGGCT	ACAGCCGAC	CTACAAACAG	GCACAGCACT	850
87058	801	-----	-----	-----	-----	850
87058.6	801 CAAGATCTGT	GACCTGGCT	ACAGCCGAC	CTACAAACAG	GCACAGCACT	850
87058.8	801 CAAGATCTGT	GACCTGGCT	ACAGCCGAC	CTACAAACAG	GCACAGCACT	850
87058.16	801	-----	-----	-----	-----	850
	860	870	880	890	900	
caphepsin	851 ACGGATACAA	TTCCTACAGC	GTCTCCATA	GGGAGAAGGA	CATCATGGCC	900
87058	851	-----	-----	-----	-----	900
87058.6	851 ACGGATACAA	TTCCTACAGC	GTCTCCATA	GGGAGAAGGA	CATCATGGCC	900
87058.8	851 ACGGATACAA	TTCCTACAGC	GTCTCCATA	GGGAGAAGGA	CATCATGGCC	900
87058.16	851	-----	-----	-----	-----	900
	910	920	930	940	950	
caphepsin	901 GAGATCTACA	AAAACGGCCC	CGTGGAGGGA	GCTTCTCTG	TGTATTCGGA	950
87058	901	-----	-----	-----	-----	950
87058.6	901 GAGATCTACA	AAAACGGCCC	CGTGGAGGGA	GCTTCTCTG	TGTATTCGGA	950
87058.8	901 GAGATCTACA	AAAACGGCCC	CGTGGAGGGA	GCTTCTCTG	TGTATTCGGA	950
87058.16	901	-----	-----	-----	-----	950
	960	970	980	990	1000	
caphepsin	951 CTTCTCTGCTC	TACAGTCAG	GAGTGTACCA	ACACGTCAAC	GGAGAGATGA	1000
87058	951	-----	-----	-----	-----	1000
87058.6	951 CTTCTCTGCTC	TACAGTCAG	GAGTGTACCA	ACACGTCAAC	GGAGAGATGA	1000
87058.8	951	-----	-----	-----	-----	1000
87058.16	951	-----	-----	-----	-----	1000

FIGURE 8C

18/20

		1010	1020	1030	1040	1050	
caphepsin		1001 TGGGTGGGCA	TGOCATCCGC	ATCCTGGGCT	GGGGACTGGA	GAATGCCACA	1050
67058	1001	-----	-----	-----	-----	-----	1050
67058.6	1001	TGGGTGGGCA	TGOCATCCGC	ATCCTGGGCT	GGGGACTGGA	GAATGCCACA	1050
67058.8	1001	-----	-----	-----	-----	-----	1050
67058.16	1001	-----	-----	-----	-----	-----	1050
		1060	1070	1080	1090	1100	
caphepsin		1051 cCCTACTGCG	TGGTTGCGAA	CTCCTGGAAC	ACTGACTGGG	GTGACAAATGG	1100
67058	1051	-----	-----	-----	-----	-----	1100
67058.6	1051	-----	-----	-----	-----	-----	1100
67058.8	1051	cCCTACTGCG	TGGTTGgGAA	CTCCTGGAAC	ACTGACTGGG	GTGACAAATGG	1100
67058.16	1051	-----	-----	-----	-----	-----	1100
		1110	1120	1130	1140	1150	
caphepsin		1101 CTTCTTTAAA	ATACTCAGAG	GACAGGATCA	CTGTGGAATC	GAATCAGAAG	1150
67058	1101	-----	-----	-----	-----	-----	1150
67058.6	1101	-----	-----	-----	-----	-----	1150
67058.8	1101	-----	-----	-----	-----	-----	1150
67058.16	1101	-----	-----	-----	-----	-----	1150
		1160	1170	1180	1190	1200	
caphepsin		1151 TGGTGGCTGG	AATTCGACGC	ACCGATCAGT	ACTGGGAAGA	GATCTAACTT	1200
67058	1151	TGGTGGCTGG	AATTCGACGC	ACCGATCAGT	ACTGGGAAGA	GATCTAACTT	1200
67058.6	1151	-----	-----	-----	-----	-----	1200
67058.8	1151	-----	-----	-----	-----	-----	1200
67058.16	1151	-----	-----	-----	-----	-----	1200
		1210	1220	1230	1240	1250	
caphepsin		1201 GCGGTGGGCC	TGTCGTGCGA	GTCCTGGGGG	CGAGATCGGG	GTAGAAATGC	1250
67058	1201	GCGGTGGGCC	TNTCGTGCGA	GTCCTGGGGG	CGAGATCGGG	GTAGAAATGC	1250
67058.6	1201	-----	-----	-----	-----	-----	1250
67058.8	1201	-----	-----	-----	-----	-----	1250
67058.16	1201	-----	-----	-----	-----	-----	1250
		1260	1270	1280	1290	1300	
caphepsin		1251 ATTTTATCT	TTAAGTTCAC	GTAAGATACA	AGTTTCAGGc	AGGGTCTgAA	1300
67058	1251	ATTTTATCT	TTAAGTTCAC	GTAAGATACA	AGTTTCAGGc	AGGGTCTnAA	1300
67058.6	1251	-----	-----	-----	-----	-----	1300
67058.8	1251	-----	-----	-----	-----	-----	1300
67058.16	1251	-----	-----	-----	-----	-----	1300
		1310	1320	1330	1340	1350	
caphepsin		1301 GGACTGGATT	GGCCAAAACAT	CAGACCTGTC	TTCCAAAGGAG	ACCRAGTCCT	1350
67058	1301	GGcCTGGATT	GGCCAAAACAT	CAGACCTGTC	1350
67058.6	1301	1350
67058.8	1301	1350
67058.16	1301	1350

FIGURE 8D

	1360	1370	1380	1390	1400	
caphepsin	1351	GGCTACATCC	CAGCTCTGCG	TTCAGTGC	GACAGGCCAT	GTGAGCCACC
87058	1351	1400
87058.6	1351	1400
87058.8	1351	1400
87058.16	1351	1400
	1410	1420	1430	1440	1450	
caphepsin	1401	GCTGCCAGCA	CAGAGCGTCC	TTCCCCCTGT	AGACTCTGTC	CGTGGGAGTA
87058	1401	1450
87058.6	1401	1450
87058.8	1401	1450
87058.16	1401	1450
	1460	1470	1480	1490	1500	
caphepsin	1451	CCTGCTGCC	AGCTGCTGTC	GCCCCCTCG	TGTTCCATTC	ATCTCCAGGG
87058	1451	1500
87058.6	1451	1500
87058.8	1451	1500
87058.16	1451	1500
	1510	1520	1530	1540	1550	
caphepsin	1501	AGCAAGACAG	AGACGCCAGGA	TGCAAAACGGG	AGTTCTAAC	AGGATGAAAG
87058	1501	1550
87058.6	1501	1550
87058.8	1501	1550
87058.16	1501	1550
	1560	1570	1580	1590	1600	
caphepsin	1551	TTCCGCCATC	AGTTCCGCCA	GTACCTCCAA	GCAAGTAGCT	TTCCACATT
87058	1551	1600
87058.6	1551	1600
87058.8	1551	1600
87058.16	1551	1600
	1610	1620	1630	1640	1650	
caphepsin	1601	GTCACAGAAA	TCAGAGGAGA	GATCTGTG	GGACGCCCTT	GGAGAACGCC
87058	1601	1650
87058.6	1601	1650
87058.8	1601	1650
87058.16	1601	1650

FIGURE 8E

20/20

	1660	1670	1680	1690	1700	
capthepsin	1651 AGTCCTGAGG TCCCTCTGCA TCTATCGAGT TTGCAATGTC ACAGACCTTC					1700
87058	1651	1700
87058.6	1651	1700
87058.8	1651	1700
87058.16	1651	1700
	1710	1720	1730	1740	1750	
capthepsin	1701 TGATCTTGTG CTCAGCATGA TTCTTTATAA GAAGTTTAT TTTCTGTGCA					1750
87058	1701	1750
87058.6	1701	1750
87058.8	1701	1750
87058.16	1701	1750
	1760	1770	1780	1790	1800	
capthepsin	1751 CTCTGCTAAT CTGTCGGGCG AGGCACTGGA ACAGCGGGAG CCTGTCCTGC					1800
87058	1751	1800
87058.6	1751	1800
87058.8	1751	1800
87058.16	1751	1800
	1810	1820	1830	1840	1850	
capthepsin	1801 TTTCGAGTTT GCTCTTAAT GAGGGCGTC AAAAAAGAAC CAACTGGCA					1850
87058	1801	1850
87058.6	1801	1850
87058.8	1801	1850
87058.16	1801	1850
	1860	1870	1880	1890	1900	
capthepsin	1851 GGAGTTGTTT CTGACCGCT GATCTCTACT ACCACAGGA AATAAGTTA					1900
87058	1851	1900
87058.6	1851	1900
87058.8	1851	1900
87058.16	1851	1900
	1910	1920	1930	1940	1950	
capthepsin	1901 GGAGGAAACCA CCTTTTCTG TTTTTGAAA ATTACAGCTT CACCTGTCA					1950
87058	1901	1950
87058.6	1901	1950
87058.8	1901	1950
87058.16	1901	1950
	1960	1970	1980	1990	2000	
capthepsin	1951 AGTTAACAGG GATGCGTGT GCGATAAAA GGTTCTCCA ACTTGA...					2000
87058	1951	2000
87058.6	1951	2000
87058.8	1951	2000
87058.16	1951	2000

FIGURE 8F